fluorouracil has been researched along with Leukocytopenia in 411 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Capecitabine and paclitaxel are established effective treatments, alone and combined with other cytotoxic and targeted agents, for metastatic breast cancer (MBC)." | 9.19 | Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. ( Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW, 2014) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 9.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "A phase-I clinical study of a combination therapy of vinorelbine and capecitabine was conducted in anthracycline- and taxane-pretreated patients with advanced/recurrent breast cancer." | 9.12 | [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ( Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 9.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 9.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma." | 9.11 | First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 9.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 9.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 9.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 9.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 9.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 9.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 9.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days." | 9.07 | A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. ( Amato, C; Callari, A; Cannata, G; Cipolla, C; Cusimano, MP; Garascia, C; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A, 1994) |
| "A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)." | 9.07 | A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 9.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 9.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 7.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 7.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 7.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 7.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 7.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 7.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| " In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used." | 7.68 | The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 7.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "C57BL mice were injected intravenously with an antitumor immunopotentiating polysaccharide, lentinan, to assess its effect on granulopoiesis in normal mice as well as its ability to enhance the recovery from leukopenia induced by 5-fluorouracil (5-FU)." | 7.67 | [Granulopoietic effects of lentinan in mice: effects on GM-CFC and 5-FU-induced leukopenia]. ( Hayami, T; Kumada, K; Kurahashi, Y; Matsuo, T; Nishida, S; Takagi, T, 1987) |
| "The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary." | 7.67 | 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 7.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "The binding of 5-fluorouracil to polybutylcyanoacrylate nanoparticles yielded an enhanced efficacy against Crocker sarcoma S 180 and a higher toxicity of the drug measured by induced leukopenia, body weight loss and premature death." | 7.66 | Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. ( Hartmann, HR; Kreuter, J, 1983) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 7.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)." | 7.66 | 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980) |
| "2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation." | 6.73 | [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 6.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 6.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 5.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 5.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| "Gastrointestinal mucositis is a common side effect of cancer chemotherapy." | 5.37 | Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Brito, GA; Cunha, FQ; Justino, PF; Lima-Junior, RC; Mota, JM; Ribeiro, RA; Soares, PM; Souza, MH, 2011) |
| " This study examines the effect of parameters reflecting the body size, body weight and height, body mass index (BMI), and body surface area (BSA) on the depth of the blood leukocyte nadir in breast cancer patients receiving adjuvant chemotherapy, when drug dosing was based on the BSA." | 5.31 | Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. ( Blomqvist, C; Joensuu, H; Poikonen, P, 2001) |
| "The subjects were 50 advanced gastric cancer patients treated with FP." | 5.31 | Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? ( Boku, N; Muto, M; Nagashima, F; Ohtsu, A; Shinkai, T; Yoshida, S, 2001) |
| "The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 5.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "Meth-A fibrosarcoma was subcutaneously inoculated into the backs of syngeneic BALB/c mice." | 5.28 | Comparative effects of a recombinant and a mutein type of granulocyte colony stimulating factor on the growth of Meth-A fibrosarcoma with 5-fluorouracil chemotherapy. ( Fukumoto, M; Kawabata, K; Masai, Y; Morimoto, H; Nio, Y; Shiraishi, T; Tobe, T; Tseng, CC; Tsubono, M, 1992) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 5.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer." | 5.22 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016) |
| "Patients with previously untreated thoracic AEC who had T4 tumors or M1 lymph node metastasis (M1 LYM), or both, received intravenous infusions of docetaxel (35 mg/m(2)) and cisplatin (40 mg/m(2)) on day 1 and a continuous intravenous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5, every 2 weeks, plus concurrent radiation." | 5.19 | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). ( Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S, 2014) |
| "Capecitabine and paclitaxel are established effective treatments, alone and combined with other cytotoxic and targeted agents, for metastatic breast cancer (MBC)." | 5.19 | Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. ( Allred, JB; Fitch, TR; Hobday, TJ; Liu, H; Lyss, AP; Northfelt, DW; Perez, EA; Rodacker, MW, 2014) |
| "The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer." | 5.17 | FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013) |
| "Sequential doxorubicin/paclitaxel (AT) followed by CMF treatment was shown to be an active neoadjuvant chemotherapy regimen in the first European Cooperative Trial in Operable Breast Cancer (ECTO I trial)." | 5.16 | Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II). ( Bari, M; Ciruelos, E; De Benedictis, E; Dittrich, C; Gaion, F; Gomez, P; Lluch, A; Luca, G; Mansutti, M; Morandi, P; Pavesi, L; Semiglazov, V; Valagussa, P; Zamagni, C; Zambetti, M, 2012) |
| "After a first standard dosed FEC course (5-fluorouracil 600 mg/m(2), epirubicin 60 mg/mg(2) and cyclophosphamide 600 mg/m(2)), patients who did not reach leukopenia grade III or IV were randomised to standard doses (group standard) or doses tailored to achieve grade III leukopenia (group tailored) at courses 2-7." | 5.15 | Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1. ( Ahlgren, J; Andersson, M; Bengtsson, NO; Bergh, J; Bjerre, K; Blomqvist, C; Edlund, P; Holmberg, SB; Jakobsen, E; Lindman, H; Mouridsen, H; Møller, S, 2011) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 5.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "In this multicentre, open-label, phase III, randomised controlled trial, 4162 women (aged >18 years) with node-positive or high-risk node-negative operable early breast cancer were randomly assigned by computer-generated permuted block randomisation to receive FEC (fluorouracil 600 mg/m(2), epirubicin 60 mg/m(2), cyclophosphamide 600 mg/m(2) at 3-weekly intervals) for four cycles followed by docetaxel (100 mg/m(2) at 3-weekly intervals) for four cycles (n=2073) or control (n=2089)." | 5.14 | Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. ( Barrett-Lee, P; Bartlett, JM; Bliss, JM; Bloomfield, D; Cameron, D; Canney, P; Coleman, R; Dowsett, M; Earl, H; Ellis, I; Ellis, P; Hall, E; Hopwood, P; Johnson, L; Johnston, S; O'Reilly, S; Peckitt, C; Poole, C; Smith, I; Twelves, C; Verrill, M; Wardley, A; Yarnold, J, 2009) |
| "In a multi-centre, randomised, controlled study, 1016 premenopausal women received seven series of FEC (F: fluorouracil, E: epirubicin and C: cyclophosphamide) for early stage breast cancer." | 5.14 | The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study. ( Ahlgren, J; Andersen, J; Andersson, M; Bergh, J; Bjerre, K; Blomquist, C; Lidbrink, E; Lindman, H; Mouridsen, H; Rosendahl, M, 2009) |
| "To assess the predictive value of polymorphisms in dihydropyrimidine dehydrogenase (DPYD ), thymidylate synthase (TYMS ), and methylene tetrahydrofolate reductase (MTHFR ) and of nongenetic factors for severe leukopenia, diarrhea, and mucositis related to fluorouracil (FU) treatment." | 5.13 | Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. ( Blievernicht, J; Bokemeyer, C; Dippon, J; Eichelbaum, M; Fischer, J; Hofmann, U; Kerb, R; Klein, K; Marx, C; Schaeffeler, E; Schwab, M; Zanger, UM, 2008) |
| "A phase-I clinical study of a combination therapy of vinorelbine and capecitabine was conducted in anthracycline- and taxane-pretreated patients with advanced/recurrent breast cancer." | 5.12 | [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ( Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 5.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "To evaluate tolerance and toxicity of high-dose epirubicin regimen CEF-100 as adjuvant therapy for breast cancer." | 5.12 | [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer]. ( Hao, XM; Hui, R; Zhang, J; Zhang, M, 2007) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 5.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma." | 5.11 | First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004) |
| "This study investigated the efficacy and tolerability of FEC 100 (epirubicin 100 mg/m2 with 5-fluorouracil 500 mg/m2 and cyclophosphamide 500 mg/m2) every 21 days as neoadjuvant chemotherapy in women with stage I-III primary operable breast cancer." | 5.11 | Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. ( Abrial, CJ; Amat, S; Chollet, PJ; Curé, HD; Feillel, VA; Ferrière, JP; Kwiatkowski, FG; Lebouëdec, G; Mouret-Reynier, MA; Penault-Llorca, FM, 2004) |
| "The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pancreas." | 5.11 | Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. ( Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A, 2005) |
| "The study includes the breast cancer female patients who had received chemotherapy (CMF, tamoxifen) and the newly diagnosed breast cancer patients, who had not received any chemotherapy." | 5.11 | Evaluation of toxicities induced by chemotherapy in breast cancer patients. ( Khanam, A; Mehreen, L, 2005) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 5.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 5.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "The purpose of this study was to examine the association between the leucocyte nadir and prognosis in breast cancer patients receiving adjuvant chemotherapy consisting of cyclophosphamide, methotrexate and fluorouracil (CMF)." | 5.09 | Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. ( Blomqvist, C; Joensuu, H; Lundin, J; Poikonen, P; Saarto, T, 1999) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 5.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 5.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| " levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder." | 5.08 | Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 5.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer." | 5.08 | Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997) |
| "The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative therapy for patients with adenocarcinomas of the rectum that extend through the bowel wall or with lymph nodes positive for tumor." | 5.08 | Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. ( Benson, AB; Cooke, E; Cummings, B; Gunderson, LL; Hollis, D; Macdonald, JS; Martenson, JA; O'Connell, MJ; Petroni, GR; Tepper, JE, 1997) |
| "Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days." | 5.07 | A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma. ( Amato, C; Callari, A; Cannata, G; Cipolla, C; Cusimano, MP; Garascia, C; Gebbia, N; Gebbia, V; Latteri, MA; Testa, A, 1994) |
| "A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)." | 5.07 | A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994) |
| " Leukopenia was severe in the first two steps of treatment, with WHO grade IV toxicity occurring in 41% of patients; however, this decreased to 10% when vindesine was deleted from the chemotherapy regimen in the last two steps." | 5.07 | Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study. ( Bauer, J; Bernasconi, S; Leyvraz, S; Monnier, P; Pasche, P, 1994) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 5.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 5.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)." | 5.06 | A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990) |
| "One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs." | 5.05 | Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. ( Bateman, JR; Chlebowski, RT; Kardinal, C; Pajak, T; Silverberg, I; Weiner, J, 1980) |
| "After en bloc resection of gastric adenocarcinoma, 180 patients were randomized to 2 years of 5-fluorouracil (5-FU) + semustine (MeCCNU) chemotherapy or to observation only." | 5.05 | Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). ( Brunner, KW; Douglass, HO; Engstrom, PF; Lavin, PT, 1985) |
| "Ninety-nine patients with advanced breast cancer were randomized to receive either cyclophosphamide continuously or a combination of cyclophosphamide, methotrexate, 5-fluorouracil and vinblastine given intermittently." | 5.04 | Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. ( Hayward, JL; Knight, RK; Rubens, RD, 1975) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "Consecutive patients with locally advanced (T2 ≥ 4 cm-T4 or N+) anal cancer scheduled for two cycles of concomitant 5-fluorouracil and mitomycin C chemotherapy were selected from an institutional database (n = 106)." | 4.02 | Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer. ( Johnsson, A; Nilsson, MP; Scherman, J, 2021) |
| "1637C>T, T546M) in ABCC11 encoding the MRP8 (multidrug resistance protein 8), a transporter of 5-fluorodeoxyuridine monophosphate, has been associated with an increased risk of 5-fluorouracil-related severe leukopenia." | 3.85 | The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. ( Aebi, S; Amstutz, U; Froehlich, TK; Hamzic, S; Joerger, M; Largiadèr, CR; Wenger, N, 2017) |
| "Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C." | 3.85 | Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017) |
| "We studied the response of hematopoietic stem cells and progenitor cells to sympatholytic reserpine in intact C57Bl/6 mice and in animals with cyclophosphamide-induced leukopenia." | 3.83 | Response of Hematopoietic Stem and Progenitor Cells to Reserpine in C57Bl/6 Mice. ( Dygai, AM; Ermakova, NN; Krupin, VA; Pakhomova, AV; Pershina, OV; Skurikhin, EG, 2016) |
| " Transplantation of bone marrow hematopoietic stem and progenitor cells from diabetic C57Bl/6 donor mice to recipient CBA mice with 5-fluorouracilinduced leukopenia accelerated regeneration of granulocytopoiesis in recipient mice." | 3.83 | Role of Hematopoietic Stem Cells in Inflammation of the Pancreas during Diabetes Mellitus. ( Choinzonov, EL; Dygai, AM; Ellinidi, VN; Ermakova, NN; Ermolaeva, LA; Goldberg, VE; Kravtsov, VY; Krupin, VA; Pershina, OV; Reikhart, DV; Skurikhin, EG; Stakheeva, MN, 2016) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 3.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 3.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine." | 3.78 | Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. ( Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| "Atorvastatin prevented mucosal damage and inflammation associated with 5-FU-induced OM, but the association of a higher dose of ATV with 5-FU induced hepatotoxicity and amplified leukopenia." | 3.77 | Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis. ( Alencar, NM; Barboza, DR; Brito, GA; Gomes, AS; Leitão, RF; Macedo, RN; Medeiros, CA; Nogueira, NA; Ribeiro, RA, 2011) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 3.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 3.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| "African-American patients with colorectal cancer were observed to have increased 5-fluorouracil (5-FU)-associated toxicity (leukopenia and anemia) and decreased overall survival compared with Caucasian patients." | 3.73 | Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. ( Desmond, RA; Diasio, RB; Fourie, J; Mattison, LK; Modak, A; Saif, MW, 2006) |
| "Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated." | 3.72 | [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004) |
| " Results indicated that the chemotherapy agent 5-fluorouracil (5-FU) administered to hamsters on days 0 and 2 produced severe leukopenia between days 4 and 7 of the trial, and that severity of oral mucositis coincided with the suppressed immune state in these animals." | 3.70 | Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster. ( Clarke, J; Edwards, B; Regester, G; Srpek, L, 1999) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "5-FU-induced leukopenia was reversed for several weeks after the administration of oral uridine." | 3.68 | Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. ( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1993) |
| "The effect of a novel synthetic compound, Y-25510, (+-)-3-[4-(2-dimethylamino-1-methylethoxy)phenyl]-1H-pyrazolo[3,4 -b] pyridine-1-acetic acid, on recovery from long-lasting leukopenia induced by 5-fluorouracil was compared with that of recombinant human granulocyte colony-stimulating factor (rhG-CSF)." | 3.68 | Enhancement of host defense by Y-25510, (+-)-3-[4-(2-dimethylamino-1-methylethoxy)phenyl]-1H-pyrazolo[3,4 -b] pyridine-1-acetic acid, a novel synthetic compound. A comparison with recombinant human granulocyte colony-stimulating factor in 5-fluorouracil-t ( Fukuda, T; Goto, K; Hisadome, M; Nomoto, K; Oe, T; Takahata, H; Terasawa, M; Tsuru, S, 1992) |
| "5-Fluorouracil (5-FU) induces a decrease in the number of peripheral leukocytes (leukopenia), which is one of the major obstacles in the chemotherapy of cancer." | 3.68 | Protective effect of SPR-901 (RBS) on the decrease of peripheral leukocyte number in 5-fluorouracil-treated mice. ( Miyazaki, H; Nomoto, K; Takeda, Y; Takeo, S; Tanaka, M; Yoshikai, Y, 1992) |
| " In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used." | 3.68 | The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 3.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Twenty-nine evaluable patients with colorectal adenocarcinoma were treated in a phase I-II trial of combination chemotherapy with a 72-h continuous infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU) with an infusion of VP-16 given at 24 and 48 h after the start of therapy." | 3.68 | A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. ( Browne, MJ; Calabresi, P; Clark, JW; Cummings, FJ; Curt, G; Posner, M; Slapak, CA; Urba, S; Weitberg, A; Wiemann, M, 1990) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "C57BL mice were injected intravenously with an antitumor immunopotentiating polysaccharide, lentinan, to assess its effect on granulopoiesis in normal mice as well as its ability to enhance the recovery from leukopenia induced by 5-fluorouracil (5-FU)." | 3.67 | [Granulopoietic effects of lentinan in mice: effects on GM-CFC and 5-FU-induced leukopenia]. ( Hayami, T; Kumada, K; Kurahashi, Y; Matsuo, T; Nishida, S; Takagi, T, 1987) |
| "The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary." | 3.67 | 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "The binding of 5-fluorouracil to polybutylcyanoacrylate nanoparticles yielded an enhanced efficacy against Crocker sarcoma S 180 and a higher toxicity of the drug measured by induced leukopenia, body weight loss and premature death." | 3.66 | Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. ( Hartmann, HR; Kreuter, J, 1983) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 3.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)." | 3.66 | 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980) |
| "Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1, plus 5-FU day 1 and 8, and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8, cyclophosphamide day 1 and methotrexate day 1 (AFCM)." | 3.66 | Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study. ( Costanzi, J; Hoogstraten, B; Kennedy, A; Maloney, TR; Palmer, RL; Rivkin, S; Samal, B; Smith, F; Thigpen, T; Tranum, B; Tucker, WG; Vaughn, CB; Wilson, H, 1978) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "Patients with advanced solid tumors received oral BKM120 daily combined with standard doses of mFOLFOX6 every 2 weeks of a 28 day cycle." | 2.80 | A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. ( Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK, 2015) |
| "Stage II and III rectal cancer patients received, after total mesorectal excision, 2 cycles of XELOX regimen (oxaliplatin 130 mg/m(2) on day 1; capecitabine 1000 mg/m(2) bid on day 1 to 14, q21), followed by capecitabine (800 mg/m(2) bid daily; 20% dose at 12:00 AM and 80% dose at 12:00 PM) administered continuously during pelvic radiation (total 50." | 2.79 | Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. ( Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F, 2014) |
| " After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2." | 2.79 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014) |
| " The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
| "Capecitabine was administered orally twice a day at a dose of 1, 250 mg/m(2) for 14-day followed by 7-day rest and oral thalidomide 100 mg was given daily without interruption until disease progression or occurrence of unacceptable toxicity." | 2.78 | [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer]. ( Li, CH; Ma, TH; Shi, SB; Tang, XY, 2013) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| "To investigate the therapeutical effect and side-effect of docetaxel combined with cisplatin (DDP) on the treatment of local advanced esophageal cancer with concomitant radiation therapy." | 2.75 | [Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy]. ( Gu, XW; Pan, YK; Xu, X; Zhang, TR; Zhao, T, 2010) |
| "To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer." | 2.74 | Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009) |
| " Pharmacokinetic assessments were conducted in cycles 1 and 3." | 2.74 | Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. ( Berg, DJ; Bernaards, C; Blanchard, R; Denlinger, CS; Dorr, A; Hambleton, J; Holden, S; Kearns, A; Kenkare-Mitra, S; Litwin, S; Lum, B; McLaughlin, S; Meropol, NJ; O'Dwyer, PJ; Redlinger, M; Spittle, C; Xu, L, 2009) |
| "This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients." | 2.74 | [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009) |
| "Capecitabine combined with fractionated cisplatin is highly effective and well tolerated as a first-line treatment for advanced gastric cancer, with comparable results to 5-Fu plus cisplatin combination therapy." | 2.73 | [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study]. ( Bai, YX; Chen, L; Chen, S; Cheng, Y; Hu, B; Jia, TZ; Jin, ML; Li, J; Liang, J; Shen, L; Shu, YQ; Wan, DS; Wang, BC; Wen, ZZ; Yin, HR; Yu, JR; Zhang, HG; Zhou, Y, 2008) |
| "This concurrent chemoradiotherapy with PFML was safe and well tolerated." | 2.73 | Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. ( Katori, H; Taguchi, T; Tsukuda, M, 2007) |
| "Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year." | 2.73 | A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Winter, K, 2007) |
| "First-line chemotherapy for 32 advanced squamous cell carcinomas of the esophagus is not effective, and early recurrences after chemotherapy were examined." | 2.73 | [Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer]. ( Aoyama, N; Minamide, J; Oota, Y; Takada, K, 2007) |
| " This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events." | 2.73 | [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis]. ( Chen, G; Ding, PR; Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, GQ; Wu, XJ; Zhou, ZW, 2007) |
| "2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation." | 2.73 | [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007) |
| "Seventy patients with advanced head and neck cancer were treated with vinorelbine and continuous 5-FU administered in a central venous catheter." | 2.73 | A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. ( Adimi, P; Andersen, LJ; Bastholt, L; Larsen, S; Lindeløv, B; McCulloch, T; Serup-Hansen, E, 2007) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions." | 2.72 | A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. ( Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006) |
| " We thus conducted a phase I/II study of gemcitabine and infusional 5-FU in Japanese patients to determine a recommended dosage for this combination and clarify efficacy and toxicity." | 2.72 | A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. ( Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H, 2006) |
| " Similar dosage and fractionation of RT was administered in both arms." | 2.71 | Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. ( Hsu, CY; Jan, JS; Jiang, RS; Liang, WM; Lin, JC; Wang, WY, 2003) |
| " We decided on a recommended dose of cisplatin of 4 mg/m(2)/day because the dosage was one level under the maximum-tolerated dose." | 2.71 | Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). ( Hirakawa, K; Hirata, K; Mitachi, Y; Nakata, B; Shirasaka, T; Tsuji, A; Yamamitsu, S, 2004) |
| "Standard chemotherapy for advanced gastric cancer remains undefined." | 2.71 | [A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer]. ( Cai, XC; Chen, Q; Chen, YG; Fan, NF; Guo, ZQ; Lu, X; Ouyang, XN; Wu, XA; Xu, S; Yang, JW; Zhang, YH, 2005) |
| "Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin." | 2.70 | Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor." | 2.70 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002) |
| "33 had squamous carcinoma and 7 adenocarcinoma; 15 were male; the locoregional metastatic ratio was 1:39; median ECOG performance status was 2 (range 1-3)." | 2.70 | A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. ( Ajarim, D; Al Fadda, M; Bazarbashi, S; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, MA, 2002) |
| " The same dosage of combine drugs were used in the two groups." | 2.70 | [Phase III clinical study of a new anticancer drug atofluding]. ( Feng, FY; Han, J; Li, L; Li, Q; Sui, GJ; Wang, PH; Zhang, Y; Zhang, YC; Zhang, ZH; Zhou, MZ; Zhu, YG, 2002) |
| " We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| "Chemotherapy resistance of renal cell carcinoma (RCC) has been attributed in large part to multidrug resistance (MDR)." | 2.70 | Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. ( Chang, YH; Chen, KK; Chen, PM; Fan, FS; Liu, JH; Wang, WS; Yang, MH; Yen, CC, 2001) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells." | 2.70 | Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002) |
| "The subjects were patients with squamous cell carcinoma of the oral cavity who had not received any therapy, comprising 7 patients with carcinoma of the tongue, 2 with buccal carcinoma, 2 with maxillary gingival carcinoma, and 1 with carcinoma of the oral floor." | 2.70 | [Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer]. ( Ando, T; Fukada, K; Hoshino, M; Kuwazawa, T; Maruoka, Y; Nishihara, N; Ogiuchi, H; Ogiuchi, Y; Okamoto, T, 2002) |
| "Fifteen patients with advanced gastric cancer undergoing palliative chemotherapy with etoposide, leucovorin and 5-fluorouracil (ELF) received for 10 days (beginning 3 days before chemotherapy) daily i." | 2.70 | Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy--a pilot study. ( Clemm, C; Draczynski, T; Linde, K; Melchart, D; Saller, R; Wagner, H; Weber, B; Weidenhammer, W; Worku, F, 2002) |
| "The first-line chemotherapy for head and neck cancer is reported to be the combination of CDDP and 5-FU." | 2.69 | [Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer]. ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1998) |
| "Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion." | 2.69 | Phase II study of paclitaxel in pretreated advanced gastric cancer. ( Cardarelli, N; Cascinu, S; Catalano, G; Giordani, P; Graziano, F; Marcellini, M; Menichetti, ET, 1998) |
| "Patients with advanced and recurrent gastric cancer were treated with this regimen as early phase II trial and its efficacy and toxicity were assessed." | 2.69 | Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer. ( Inada, T; Kikuyama, S; Miyakita, M; Ogata, Y, 1998) |
| "Thirty-six advanced or metastatic gastric cancer and chemotherapy-naïve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m2/day on days 2-4, LV 300 mg/m2/day intravenously and 5-FU 500 mg/m2/day intravenously on days 1-5, every 4 weeks." | 2.69 | Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1998) |
| "Liver metastasis from breast cancer has a poor prognosis." | 2.69 | A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group. ( Adachi, I; Ando, J; Aoyama, H; Enomoto, K; Fukutomi, T; Ikeda, T; Kanda, K; Ogita, M; Sano, M; Shimoyama, M; Tabei, T; Takashima, S; Tominaga, T, 1999) |
| "Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy." | 2.69 | Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). ( Coche-Dequeant, B; De Raucourt, D; Domenge, C; Hill, C; Lefebvre, JL; Luboinski, B; Marandas, P; Rhein, B; Sancho-Garnier, H; Stromboni-Luboinski, M; Wibault, P, 2000) |
| "N&V and leukopenia were the major side effects." | 2.68 | Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995) |
| " None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU." | 2.68 | [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma]. ( Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Shuin, T; Yao, M, 1995) |
| " l-LV was administered intravenously by a 2-hour infusion at a dosage of 250 mg/m2 and 5-FU at a dosage of 600 mg/m2, intravenously via bolus one hour after administration of l-LV had been started." | 2.68 | [A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Hirabayashi, N; Kurihara, M; Nakano, S; Ohno, T; Ohta, J; Ohtani, T; Taguchi, T; Takeda, S; Yonemura, Y, 1995) |
| " Dosing decisions in older patients are difficult and must integrate assessments of organ function, comorbidities, overall physical status, and goals of treatment, in an effort to ensure the best possible outcome for these patients." | 2.68 | Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. ( Arcangeli, G; Douglass, HO; Driscoll, DL; Meropol, NJ; Petrelli, NJ; Stein, BN, 1995) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| " Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis." | 2.68 | 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. ( Cunningham, D; Harper, P; Kerr, D; Olver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; Van Cutsem, E; Zalcberg, JR, 1995) |
| "Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)." | 2.68 | [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma]. ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996) |
| "Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin." | 2.68 | Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. ( Buckner, JC; Cascino, TL; Goldberg, RM; Kuross, SA; Levitt, R; Morton, RF; O'Fallon, JR; Scheithauer, BW; Veeder, MH; Wiesenfeld, M, 1996) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 2.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "A phase II study of protracted infusional 5-fluorouracil (5FU) combined with cisplatin (CDDP) was conducted in patients with advanced gastric carcinoma." | 2.67 | Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG). ( Kurihara, M; Morise, K; Ohtsu, A; Saito, H; Seki, S; Shimada, Y; Yoshida, S, 1994) |
| "Leukopenia was more frequent in the simultaneous than in the sequential arm (p = 0." | 2.67 | A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. ( Carlini, P; Cercato, MC; Cognetti, F; Del Vecchio, MR; Giannarelli, D; Impiombato, FA; Marzetti, F; Milella, M; Pinnarò, P, 1994) |
| "FLEP is an active combination for oesophageal cancer, especially when used preoperatively in LAD." | 2.67 | 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. ( Achterrath, W; Berger, M; Berns, T; Fink, U; Harstrick, A; Knipp, H; Meyer, HJ; Preusser, P; Stahl, M; Wilke, H, 1994) |
| "Leukocytopenia was more severe in group B." | 2.67 | [Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994) |
| " The pharmacokinetic interaction between alpha-IF and LV may play a role in the activity of this regimen." | 2.67 | Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. ( Buter, J; de Vries, EG; Mulder, NH; Roenhorst, HW; Sinnige, HA; Sleijfer, DT; Uges, DR; Verschueren, RC; Willemse, PH, 1993) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 2.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| " No serious adverse effects were observed in any of the groups." | 2.66 | [Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan]. ( Abe, O; Hattori, T; Inokuchi, K; Kasai, Y; Kikuchi, K; Komi, N; Kondo, T; Kunii, Y; Ogawa, N; Taguchi, T, 1987) |
| " This prospective study was undertaken to record possible adverse effects of surgery, external beam radiation therapy, and 5-fluorouracil (5-FU) chemotherapy in the treatment of large bowel cancer." | 2.66 | 5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route. ( Barofsky, I; Gianola, FJ; Hancock, SL; Sugarbaker, PH; Wesley, R, 1986) |
| "Fifty-eight patients with disseminated breast cancer were randomly divided into 2 study groups." | 2.66 | [Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer]. ( Borisov, AI; Korman, DB; Maslova, IA; Pines, EV, 1985) |
| "Among patients with primary head and neck cancer, the stage of the disease influenced the response rate." | 2.65 | Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. ( Archibald, SD; Browman, GP; Hryniuk, WM; Kiehl, K; Levine, MN; Russell, R; Young, JE, 1983) |
| "Leukopenia was the major cause of drug dose reduction in both groups." | 2.65 | Chemotherapy drug dose alteration due to radiation therapy in an adjuvant situation in breast cancer. ( Banerjee, TK; Greenlaw, RH; Hoehn, JL; Jacoby, C, 1984) |
| "Twenty-six patients with metastatic breast carcinoma who had measurable sites of disease were evaluated." | 2.65 | Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma. ( Aroney, RS; Dalley, DN; Levi, JA, 1980) |
| " Weekly oral 5-FU results in comparable response and survival to 5-FU given intravenously, consistent with a relatively low dose-response relationship for 5-FU in breast carcinoma." | 2.65 | Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. ( Bateman, JR; Chlebowski, RT; Pugh, RP; Weiner, JM, 1981) |
| "Leukopenia was the dose-limiting toxicity with all three regimens." | 2.64 | Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. ( Bonnet, JD; Braine, H; Costanzi, JJ; George, SL; Hoogstraten, B; Rivkin, SE; Samal, B; Thigpen, T, 1976) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| " Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 1.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| "Neoadjuvant RT for rectal cancer has lasting effects on the pelvic BM, which are demonstrable during adjuvant OxF." | 1.43 | Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy. ( Baby, R; Chen, T; Jabbour, SK; Lu, SE; Moss, RA; Newman, NB; Nissenblatt, MJ; Sidhu, MK, 2016) |
| " The chemotherapy drugs were administered as follows: 135 mg/m(2) paclitaxel on day 1, 25 mg/m(2)/day cisplatin on days 1-3, followed by continuously infused intravenous fluorouracil for 120 h at a variable dosage from 600 to 800 mg/m(2)/day, depending on prior radiation." | 1.43 | A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. ( Jiang, YX; Li, YH; Liang, Y; Luo, HY; Wang, DS; Wang, FH; Wang, Y; Wang, ZQ, 2016) |
| "Genomic DNA from 672 cancer patients treated with 5-FU monotherapy and with documented toxicity according to WHO criteria was genotyped for 12 ABCC11 tag SNPs." | 1.39 | ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. ( Arlanov, R; Ishikawa, T; Klein, K; Lang, T; Magdy, T; Schwab, M; Toyoda, Y; Winter, S; Zanger, UM, 2013) |
| "Gastrointestinal mucositis is a common side effect of cancer chemotherapy." | 1.37 | Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Brito, GA; Cunha, FQ; Justino, PF; Lima-Junior, RC; Mota, JM; Ribeiro, RA; Soares, PM; Souza, MH, 2011) |
| "5-Fluorouracil were administered intraperitoneally to mice to develop leucopenia, and the mice were treated with ZL-004." | 1.36 | [Effect of ZL-004 on raising leukocyte count]. ( Li, CG; Liu, QH; Sun, HY; Wang, GP; Xiao, L, 2010) |
| " The toxic grade for leukopenia (grade 0-2/3-4) and pathological effect (grade 3/1-2) were significantly different by univariate analysis (P = 0." | 1.35 | Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. ( Doki, Y; Eguchi, H; Imaoka, S; Ishikawa, O; Kishi, K; Miyashiro, I; Miyoshi, N; Noura, S; Ohigashi, H; Ohue, M; Sasaki, Y; Takachi, K; Yamada, T; Yano, M, 2009) |
| "104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept." | 1.35 | [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD, 2009) |
| " These effects were also observed in vivo, where the combination with piplartine but not piperine with 5-FU led to a higher tumor growth inhibition." | 1.35 | In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine. ( Alves, AP; Bezerra, DP; Costa-Lotufo, LV; de Alencar, NM; de Castro, FO; de Moraes, MO; Elmiro, FJ; Lima, MA; Lima, MW; Mesquita, RO; Pessoa, C; Silveira, ER, 2008) |
| "We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy." | 1.35 | Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008) |
| "19 out of 29 patients were colon cancer, and the other 10 were rectal cancer." | 1.34 | [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. ( Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2007) |
| "Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
| "Advanced pancreatic cancer has a poor prognosis." | 1.34 | [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer]. ( Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD, 2007) |
| " The adverse effect included grade 3 or grade 4 leukopenia in 12." | 1.34 | [Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers]. ( Bai, P; Li, XG; Ma, SK; Wu, LY; Zhang, R; Zhang, WH, 2007) |
| " These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval." | 1.33 | [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005) |
| "Grade 3 dysphagia-esophageal related to radiation was observed in 3 patients (9." | 1.33 | [Hyperfractionated radiotherapy with concurrent chemotherapy for advanced esophageal cancer]. ( Asakura, H; Hosokawa, N; Kiuchi, T; Mitani, M; Ohkawa, M; Seo, H; Takashima, H; Togami, T; Yokoe, K, 2005) |
| "Paclitaxel was administered at a dose of 80 mg/m(2), 3 times every 4 weeks." | 1.33 | [Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma]. ( Ito, S; Kodera, Y; Mochizuki, Y; Yamamura, Y, 2005) |
| "Eighteen consecutive pancreatic cancer patients presenting with isolated locoregional recurrence after surgical resection." | 1.33 | Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. ( Bruns, C; Dühmke, E; Heinemann, V; Thoma, M; Wilkowski, R, 2006) |
| " In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events." | 1.33 | [Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006) |
| " We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer." | 1.33 | [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. ( Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006) |
| "As leukopenia was seen after the first cycle, the administration doses were reduced and GTX has been continued for a total 13 cycles." | 1.33 | [Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. ( Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H, 2006) |
| "Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy." | 1.32 | Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. ( Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC, 2003) |
| "We present a case of colon cancer with idiopathic leukopenia who tolerated chemotherapy without worsening of leukopenia." | 1.32 | Adjuvant therapy of colon cancer in idiopathic leukopenia. ( Mehdi, SA; Pervez, H; Potti, A, 2003) |
| "We conducted a pilot study of nedaplatin + 5-fluorouracil (5-FU) combined with radiotherapy for 29 patients with primary advanced (stage IV) esophageal cancer." | 1.32 | [Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer]. ( Eguchi, R; Hayashi, K; Ide, H; Mitsuhashi, M; Nakamura, T; Narumiya, K; Ota, M; Takasaki, K, 2003) |
| "Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks." | 1.32 | [Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study]. ( Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H, 2003) |
| "In patients with liver metastases from colorectal cancer, survival can be increased by hepatic resection." | 1.32 | Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. ( Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D, 2004) |
| "The study included 32 colorectal cancer patients; apoptosis was determined by annexin-V binding and light-scatter morphology before and after drug infusion." | 1.32 | Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes. ( Drucker, L; Kimhi, O; Lahav, M; Lishner, M; Neumann, A; Radnay, J; Shapira, J; Shapiro, H; Yarkoni, S, 2004) |
| "30 colorectal cancer patients were enrolled into the study to receive adjuvant chemotherapy 2 weeks after cured resection." | 1.32 | [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients]. ( Chen, G; Li, S; Liao, H; Pan, ZZ; Wan, DS; Wang, GQ; Zhou, ZW, 2004) |
| " This study examines the effect of parameters reflecting the body size, body weight and height, body mass index (BMI), and body surface area (BSA) on the depth of the blood leukocyte nadir in breast cancer patients receiving adjuvant chemotherapy, when drug dosing was based on the BSA." | 1.31 | Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area. ( Blomqvist, C; Joensuu, H; Poikonen, P, 2001) |
| "Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU." | 1.31 | Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. ( Behnke, D; Häusler, P; Höffken, K; Raida, M; Schwabe, W; Van Gennip, AH; Van Kuilenburg, AB, 2001) |
| "The subjects were 50 advanced gastric cancer patients treated with FP." | 1.31 | Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities? ( Boku, N; Muto, M; Nagashima, F; Ohtsu, A; Shinkai, T; Yoshida, S, 2001) |
| "The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 1.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
| "Isoliquiritigenin is a chalcone isolated from licorice and shallots." | 1.31 | Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. ( Baba, M; Endo, H; Hamamoto, T; Joichi, Y; Kaneko, S; Morita, T; Nishino, H; Okada, Y; Okuyama, T; Tokue, A; Yamazaki, S, 2002) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| " Our preliminary data indicate that postradiation adjuvant chemotherapy with a weekly FP regimen at our dosage is not recommended for high-risk NPC." | 1.29 | Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma. ( Hsu, CY; Jan, JS; Lin, JC, 1996) |
| " injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg." | 1.28 | Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. ( Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992) |
| "Meth-A fibrosarcoma was subcutaneously inoculated into the backs of syngeneic BALB/c mice." | 1.28 | Comparative effects of a recombinant and a mutein type of granulocyte colony stimulating factor on the growth of Meth-A fibrosarcoma with 5-fluorouracil chemotherapy. ( Fukumoto, M; Kawabata, K; Masai, Y; Morimoto, H; Nio, Y; Shiraishi, T; Tobe, T; Tseng, CC; Tsubono, M, 1992) |
| " This has been explored in non-Hodgkin lymphoma, osteogenic sarcoma and bladder cancer with improved results using intensive, weekly dosing schemas." | 1.28 | Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer. ( Comis, RL; Hudes, GR; Langer, CJ; Levy, MH; Litwin, S; O'Dwyer, PJ; Padavic-Shaller, K; Walczak, J, 1991) |
| "The 36 patients with breast cancer were divided into two groups." | 1.28 | [The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer]. ( Hagiwara, M; Kanasugi, K; Komoriyama, H; Morikubo, M; Oikawa, H; Satoh, T; Tsukikawa, S; Yamaguchi, S, 1990) |
| " Mice bearing murine renal cancer (Renca) were also protected from the acute toxic effects of Cy (450 mg/kg) by pretreatment with rhIL-1 alpha." | 1.28 | Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy. ( Futami, H; Jansen, R; Keller, J; Longo, DL; MacPhee, MJ; McCormick, K; Oppenheim, JJ; Ruscetti, FW; Wiltrout, RH, 1990) |
| "This study observed the effect of chemotherapy combined with Chinese herbs and western drugs on white blood cell count in 31 patients with gastric cancer." | 1.28 | [Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients]. ( Chen, JZ, 1990) |
| "The authors treated 10 cases of malignant gliomas with intra-arterial chemotherapy after osmotic blood-brain barrier disruption." | 1.28 | [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption]. ( Hosoya, T; Nakai, O; Takahama, H; Takanashi, T; Yamada, K, 1989) |
| "Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer." | 1.28 | [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989) |
| "Twelve patients with advanced colorectal cancer were subjected to alternating cycles of treatment with low immunomodulating doses of recombinant alpha-interferon (alpha IFN) + 5-fluorouracil (5FU) or with 5FU alone." | 1.28 | Immunochemotherapy of advanced colorectal cancer with alpha-interferon and 5-fluorouracil. 1. Toxicological studies. ( Bonmassar, E; Bonmassar, G; Cucchiara, G; De Vecchis, L; Lagomarsino Caprino, M; Nunziata, C; Picconi, A; Ricci, F, 1989) |
| "Overall median survival was 352 days in colon cancer and 449 days in gastric cancer." | 1.28 | [A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. ( Arai, Y; Endo, T; Kido, C; Miyake, Y; Sakamoto, K, 1989) |
| "Leukopenia was reversed for several weeks but thrombocytopenia was not." | 1.28 | Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine. ( Laurensse, E; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1989) |
| "Sixty-six patients with advanced colorectal cancer were treated with 5-fluorouracil, Mitomycin C, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea." | 1.27 | The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer. ( Chapman, J; Chinn, B; Demitrish, MM; Enochs, K; Garland, M; Groshko, G; Pederson, B; Rocchio, R; Vaughn, CB; Ward, D, 1986) |
| "Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d." | 1.27 | High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 1.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "A recently developed model of the human granulpoietic system had been used to analyze the toxic effects of 5-fluorouracil administered to cancer patients." | 1.26 | Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis. ( Blumenson, LE; Bross, ID, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 141 (34.31) | 18.7374 |
| 1990's | 102 (24.82) | 18.2507 |
| 2000's | 108 (26.28) | 29.6817 |
| 2010's | 53 (12.90) | 24.3611 |
| 2020's | 7 (1.70) | 2.80 |
| Authors | Studies |
|---|---|
| Meirovitz, A | 1 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 1 |
| Yao, H | 1 |
| Xu, H | 1 |
| Qiu, S | 1 |
| Chen, J | 1 |
| Lin, Z | 1 |
| Zhu, J | 1 |
| Sun, X | 1 |
| Gao, Q | 1 |
| Chen, X | 1 |
| Xi, C | 1 |
| Huang, D | 2 |
| Zhang, F | 1 |
| Gao, S | 1 |
| Wang, Z | 1 |
| Zhang, J | 3 |
| Liu, X | 1 |
| Ren, G | 1 |
| Tao, X | 1 |
| Li, M | 1 |
| Chen, W | 1 |
| Zhao, Y | 1 |
| Song, R | 1 |
| Jia, Y | 1 |
| Zhang, X | 1 |
| Zhang, S | 1 |
| Wu, C | 1 |
| Zhang, R | 2 |
| Guo, Z | 2 |
| Panchenko, AV | 1 |
| Tyndyk, ML | 1 |
| Maydin, MA | 1 |
| Baldueva, IA | 1 |
| Artemyeva, AS | 1 |
| Kruglov, SS | 1 |
| Kireeva, GS | 1 |
| Golubev, AG | 1 |
| Belyaev, AM | 1 |
| Anisimov, VN | 1 |
| Wagner, AD | 1 |
| Grothey, A | 1 |
| Andre, T | 1 |
| Dixon, JG | 1 |
| Wolmark, N | 1 |
| Haller, DG | 1 |
| Allegra, CJ | 1 |
| de Gramont, A | 1 |
| VanCutsem, E | 1 |
| Alberts, SR | 1 |
| George, TJ | 1 |
| O'Connell, MJ | 4 |
| Twelves, C | 2 |
| Taieb, J | 1 |
| Saltz, LB | 1 |
| Blanke, CD | 1 |
| Francini, E | 1 |
| Kerr, R | 1 |
| Yothers, G | 1 |
| Seitz, JF | 2 |
| Marsoni, S | 1 |
| Goldberg, RM | 3 |
| Shi, Q | 1 |
| Kobayashi, N | 2 |
| Omae, K | 1 |
| Horita, Y | 1 |
| Ueno, H | 2 |
| Mizuno, N | 1 |
| Uesugi, K | 1 |
| Sudo, K | 1 |
| Ozaka, M | 1 |
| Hayashi, H | 2 |
| Okano, N | 1 |
| Kamei, K | 1 |
| Yamaguchi, A | 1 |
| Kobayashi, S | 1 |
| Suzuki, S | 1 |
| Ishihara, S | 1 |
| Uchiyama, T | 1 |
| Todaka, A | 1 |
| Fukutomi, A | 1 |
| Nilsson, MP | 1 |
| Johnsson, A | 1 |
| Scherman, J | 1 |
| Kumabe, A | 1 |
| Zenda, S | 1 |
| Motegi, A | 1 |
| Onozawa, M | 2 |
| Nakamura, N | 1 |
| Kojima, T | 2 |
| Daiko, H | 1 |
| Shigematsu, N | 1 |
| Akimoto, T | 1 |
| Eckstrom, J | 1 |
| Bartels, T | 1 |
| Abraham, I | 1 |
| Patel, H | 1 |
| Elquza, E | 1 |
| Scott, AJ | 1 |
| Malangone, S | 1 |
| Hollings, J | 1 |
| McBride, A | 1 |
| Oyaga-Iriarte, E | 1 |
| Insausti, A | 1 |
| Sayar, O | 1 |
| Aldaz, A | 1 |
| Bajetta, E | 2 |
| Pietrantonio, F | 1 |
| Buzzoni, R | 2 |
| Ferrario, E | 1 |
| Valvo, F | 1 |
| Mariani, L | 1 |
| Dotti, KF | 1 |
| Biondani, P | 1 |
| Formisano, B | 1 |
| Gevorgyan, A | 1 |
| Grassi, P | 1 |
| Di Bartolomeo, M | 1 |
| Alici, S | 1 |
| Buyukberber, S | 1 |
| Alkis, N | 1 |
| Benekli, M | 1 |
| Ozkan, M | 2 |
| Bilici, A | 1 |
| Demirci, U | 1 |
| Karaca, H | 2 |
| Arpaci, E | 1 |
| Gumus, M | 1 |
| Altunbas, M | 1 |
| Dane, F | 1 |
| Turk, HM | 1 |
| Saridaki, Z | 1 |
| Lambrodimou, G | 1 |
| Kachris, S | 1 |
| Makrantonakis, P | 1 |
| Boukovinas, I | 1 |
| Polyzos, A | 1 |
| Anagnostopoulos, A | 1 |
| Athanasiadis, A | 1 |
| Stoltidis, D | 1 |
| Georgoulias, V | 1 |
| Souglakos, J | 1 |
| Köhne, CH | 1 |
| Bedenne, L | 1 |
| Carrato, A | 2 |
| Bouché, O | 1 |
| Popov, I | 1 |
| Gaspà, L | 1 |
| Valladares, M | 1 |
| Rougier, P | 2 |
| Gog, C | 1 |
| Reichardt, P | 1 |
| Wils, J | 2 |
| Pignatti, F | 1 |
| Biertz, F | 1 |
| Ba, Y | 2 |
| Xiong, J | 1 |
| Xu, N | 2 |
| Yan, Z | 2 |
| Zhuang, Z | 1 |
| Yu, Z | 3 |
| Wan, H | 1 |
| Zhang, Y | 4 |
| Deng, T | 2 |
| Zheng, R | 1 |
| Hu, C | 1 |
| Wang, M | 1 |
| Yao, Y | 2 |
| Meng, J | 1 |
| Shi, SB | 1 |
| Ma, TH | 1 |
| Tang, XY | 1 |
| Li, CH | 1 |
| Magdy, T | 1 |
| Arlanov, R | 1 |
| Winter, S | 1 |
| Lang, T | 1 |
| Klein, K | 2 |
| Toyoda, Y | 1 |
| Ishikawa, T | 2 |
| Schwab, M | 2 |
| Zanger, UM | 2 |
| Kochi, M | 2 |
| Akiyama, Y | 1 |
| Aoki, T | 1 |
| Hagiwara, K | 1 |
| Takahashi, T | 2 |
| Hironaka, K | 1 |
| Teranishi, F | 1 |
| Osuka, F | 1 |
| Takeuchi, M | 1 |
| Fujii, M | 5 |
| Nakajima, T | 1 |
| Bazan, JG | 2 |
| Luxton, G | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| Hancock, SL | 2 |
| Kapp, DS | 1 |
| Kidd, EA | 1 |
| Koong, AC | 1 |
| Chang, DT | 2 |
| Kajiura, S | 1 |
| Hosokawa, A | 2 |
| Yoshita, H | 1 |
| Ueda, Y | 1 |
| Ueda, A | 1 |
| Mihara, H | 1 |
| Ando, T | 3 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Ogawa, K | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Woo, SM | 1 |
| Lee, WJ | 1 |
| Kim, JH | 2 |
| Kim, DH | 1 |
| Han, SS | 1 |
| Park, SJ | 1 |
| Kim, TH | 1 |
| Lee, JH | 2 |
| Koh, YH | 1 |
| Hong, EK | 1 |
| Dong, L | 1 |
| Li, J | 6 |
| Lou, XP | 1 |
| Miao, JH | 1 |
| Lu, P | 1 |
| Chang, ZW | 1 |
| Han, ZF | 1 |
| Higuchi, K | 1 |
| Komori, S | 1 |
| Tanabe, S | 1 |
| Katada, C | 1 |
| Azuma, M | 1 |
| Ishiyama, H | 1 |
| Sasaki, T | 3 |
| Ishido, K | 1 |
| Katada, N | 1 |
| Hayakawa, K | 1 |
| Koizumi, W | 1 |
| Bozkurt, O | 1 |
| Ozaslan, E | 1 |
| Baldane, S | 1 |
| Berk, V | 1 |
| Inanc, M | 1 |
| Duran, AO | 1 |
| Dikilitas, M | 1 |
| Er, O | 1 |
| Nakamura, T | 4 |
| Yamashita, K | 1 |
| Sato, T | 1 |
| Ema, A | 1 |
| Naito, M | 1 |
| Watanabe, M | 1 |
| Miwa, K | 1 |
| Oki, E | 1 |
| Emi, Y | 1 |
| Saeki, H | 1 |
| Kusumoto, T | 1 |
| Akagi, Y | 1 |
| Ogata, Y | 2 |
| Samura, H | 1 |
| Tokunaga, S | 1 |
| Ishikawa, H | 1 |
| Tanaka, T | 3 |
| Sueyoshi, S | 2 |
| Higashi, H | 1 |
| Matsuda, H | 1 |
| Touyama, T | 1 |
| Maehara, Y | 2 |
| Balboa-Beltrán, E | 1 |
| Duran, G | 1 |
| Lamas, MJ | 1 |
| Carracedo, A | 1 |
| Barros, F | 1 |
| McRee, AJ | 1 |
| Sanoff, HK | 1 |
| Carlson, C | 1 |
| Ivanova, A | 1 |
| O'Neil, BH | 1 |
| Skurikhin, EG | 2 |
| Ermakova, NN | 2 |
| Pershina, OV | 2 |
| Krupin, VA | 2 |
| Pakhomova, AV | 1 |
| Dygai, AM | 2 |
| Ermolaeva, LA | 1 |
| Stakheeva, MN | 1 |
| Choinzonov, EL | 1 |
| Goldberg, VE | 1 |
| Reikhart, DV | 1 |
| Ellinidi, VN | 1 |
| Kravtsov, VY | 1 |
| Hamzic, S | 1 |
| Wenger, N | 1 |
| Froehlich, TK | 1 |
| Joerger, M | 1 |
| Aebi, S | 1 |
| Largiadèr, CR | 1 |
| Amstutz, U | 1 |
| Newman, NB | 1 |
| Sidhu, MK | 1 |
| Baby, R | 1 |
| Moss, RA | 1 |
| Nissenblatt, MJ | 1 |
| Chen, T | 1 |
| Lu, SE | 1 |
| Jabbour, SK | 1 |
| Zhao, L | 1 |
| Liu, R | 1 |
| Zhang, Z | 1 |
| Li, T | 2 |
| Li, F | 1 |
| Liu, H | 2 |
| Li, G | 1 |
| Wang, Y | 1 |
| Wang, ZQ | 1 |
| Jiang, YX | 1 |
| Wang, FH | 1 |
| Luo, HY | 1 |
| Liang, Y | 1 |
| Wang, DS | 1 |
| Li, YH | 2 |
| Lee, AY | 1 |
| Golden, DW | 1 |
| Kopec, M | 1 |
| Pelizzari, CA | 1 |
| Aggarwal, S | 1 |
| Liauw, SL | 1 |
| Huang, HQ | 1 |
| Cai, QQ | 1 |
| Lin, XB | 1 |
| Wang, AL | 1 |
| Bu, Q | 1 |
| Hu, XH | 1 |
| Pan, ZH | 1 |
| Shuang, YR | 1 |
| Guan, ZZ | 1 |
| Wang, ZH | 1 |
| Guo, J | 1 |
| Chen, Z | 1 |
| Li, CZ | 1 |
| Sheng, LJ | 1 |
| Zhou, DG | 1 |
| Liu, B | 1 |
| Liu, J | 1 |
| Wang, QC | 1 |
| Zhang, EN | 1 |
| Horisberger, K | 1 |
| Treschl, A | 1 |
| Mai, S | 1 |
| Barreto-Miranda, M | 1 |
| Kienle, P | 1 |
| Ströbel, P | 1 |
| Erben, P | 1 |
| Woernle, C | 1 |
| Dinter, D | 1 |
| Kähler, G | 1 |
| Hochhaus, A | 3 |
| Post, S | 1 |
| Willeke, F | 1 |
| Wenz, F | 1 |
| Hofheinz, RD | 3 |
| Miyoshi, N | 1 |
| Yano, M | 2 |
| Takachi, K | 1 |
| Kishi, K | 1 |
| Noura, S | 1 |
| Eguchi, H | 1 |
| Yamada, T | 1 |
| Miyashiro, I | 1 |
| Ohue, M | 1 |
| Ohigashi, H | 1 |
| Sasaki, Y | 1 |
| Ishikawa, O | 1 |
| Doki, Y | 2 |
| Imaoka, S | 1 |
| Hu, B | 1 |
| Yu, JR | 1 |
| Wen, ZZ | 1 |
| Shu, YQ | 1 |
| Wang, BC | 1 |
| Yin, HR | 1 |
| Chen, L | 2 |
| Bai, YX | 1 |
| Liang, J | 1 |
| Cheng, Y | 1 |
| Shen, L | 4 |
| Zhou, Y | 1 |
| Zhang, HG | 1 |
| Wan, DS | 3 |
| Chen, S | 1 |
| Jia, TZ | 1 |
| Jin, ML | 2 |
| Qin, TJ | 1 |
| An, GL | 1 |
| Zhao, XH | 1 |
| Tian, F | 1 |
| Li, XH | 1 |
| Lian, JW | 1 |
| Pan, BR | 1 |
| Gu, SZ | 1 |
| Raoul, JL | 1 |
| Van Laethem, JL | 1 |
| Peeters, M | 1 |
| Brezault, C | 1 |
| Husseini, F | 1 |
| Cals, L | 1 |
| Nippgen, J | 1 |
| Loos, AH | 1 |
| Denlinger, CS | 1 |
| Blanchard, R | 1 |
| Xu, L | 1 |
| Bernaards, C | 1 |
| Litwin, S | 2 |
| Spittle, C | 1 |
| Berg, DJ | 1 |
| McLaughlin, S | 1 |
| Redlinger, M | 1 |
| Dorr, A | 1 |
| Hambleton, J | 1 |
| Holden, S | 1 |
| Kearns, A | 1 |
| Kenkare-Mitra, S | 1 |
| Lum, B | 1 |
| Meropol, NJ | 2 |
| O'Dwyer, PJ | 2 |
| Kovács, AF | 1 |
| Eberlein, K | 1 |
| Hülsmann, T | 1 |
| Ellis, P | 1 |
| Barrett-Lee, P | 1 |
| Johnson, L | 1 |
| Cameron, D | 1 |
| Wardley, A | 1 |
| O'Reilly, S | 1 |
| Verrill, M | 1 |
| Smith, I | 1 |
| Yarnold, J | 1 |
| Coleman, R | 1 |
| Earl, H | 1 |
| Canney, P | 1 |
| Poole, C | 1 |
| Bloomfield, D | 1 |
| Hopwood, P | 1 |
| Johnston, S | 1 |
| Dowsett, M | 1 |
| Bartlett, JM | 1 |
| Ellis, I | 1 |
| Peckitt, C | 1 |
| Hall, E | 1 |
| Bliss, JM | 1 |
| Zemanova, M | 1 |
| Petruzelka, L | 1 |
| Pazdro, A | 1 |
| Kralova, D | 1 |
| Smejkal, M | 1 |
| Pazdrova, G | 1 |
| Honova, H | 1 |
| Lou, F | 1 |
| Zhu, YH | 1 |
| Pan, HM | 1 |
| Xiao, Y | 1 |
| Lu, M | 2 |
| Zhang, XD | 3 |
| Li, Y | 2 |
| Wong, AL | 1 |
| Chou, N | 1 |
| Lee, KM | 1 |
| Ang, BW | 1 |
| Cheng, CL | 1 |
| Lee, SC | 1 |
| Oikawa, H | 2 |
| Nakamura, R | 1 |
| Nakasato, T | 1 |
| Nishimura, K | 1 |
| Sato, H | 1 |
| Ehara, S | 1 |
| Rosendahl, M | 1 |
| Ahlgren, J | 2 |
| Andersen, J | 1 |
| Bergh, J | 2 |
| Blomquist, C | 1 |
| Lidbrink, E | 1 |
| Lindman, H | 2 |
| Mouridsen, H | 2 |
| Bjerre, K | 2 |
| Andersson, M | 2 |
| Zhu, WG | 1 |
| Yu, CH | 1 |
| Han, JH | 1 |
| Zhou, XL | 1 |
| Tao, GZ | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 2 |
| Gao, F | 1 |
| Zhou, J | 1 |
| Zhang, WM | 1 |
| Chen, H | 1 |
| Xie, B | 1 |
| Zheng, JH | 1 |
| Xu, ZY | 1 |
| Lin, JR | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 2 |
| Kripp, M | 2 |
| Lukan, N | 2 |
| Merx, K | 2 |
| Hofmann, WK | 1 |
| Sperone, P | 1 |
| Ferrero, A | 1 |
| Daffara, F | 1 |
| Priola, A | 1 |
| Zaggia, B | 1 |
| Volante, M | 1 |
| Santini, D | 1 |
| Vincenzi, B | 1 |
| Badalamenti, G | 1 |
| Intrivici, C | 1 |
| Del Buono, S | 1 |
| De Francia, S | 1 |
| Kalomirakis, E | 1 |
| Ratti, R | 1 |
| Angeli, A | 2 |
| Dogliotti, L | 2 |
| Papotti, M | 1 |
| Terzolo, M | 1 |
| Berruti, A | 2 |
| Xiang, XJ | 1 |
| Qiu, F | 1 |
| Xiong, JP | 2 |
| Zhang, L | 1 |
| Yu, F | 1 |
| Feng, M | 1 |
| Zhan, ZY | 1 |
| Kong, L | 1 |
| Zhang, YW | 1 |
| Hu, CS | 1 |
| Guo, Y | 1 |
| Son, JY | 1 |
| Shin, JW | 1 |
| Wang, JH | 1 |
| Park, HJ | 1 |
| Kim, HG | 1 |
| Raghavendran, HR | 1 |
| Son, CG | 1 |
| Medeiros, CA | 1 |
| Leitão, RF | 1 |
| Macedo, RN | 1 |
| Barboza, DR | 1 |
| Gomes, AS | 1 |
| Nogueira, NA | 1 |
| Alencar, NM | 1 |
| Ribeiro, RA | 2 |
| Brito, GA | 2 |
| Sun, HY | 1 |
| Li, CG | 1 |
| Xiao, L | 1 |
| Wang, GP | 1 |
| Liu, QH | 1 |
| Soares, PM | 1 |
| Lima-Junior, RC | 1 |
| Mota, JM | 1 |
| Justino, PF | 1 |
| Cunha, FQ | 1 |
| Souza, MH | 1 |
| Zhang, TR | 1 |
| Zhao, T | 1 |
| Xu, X | 1 |
| Gu, XW | 1 |
| Pan, YK | 1 |
| Edlund, P | 1 |
| Holmberg, SB | 1 |
| Bengtsson, NO | 1 |
| Jakobsen, E | 1 |
| Møller, S | 1 |
| Blomqvist, C | 3 |
| Li, JH | 1 |
| Li, B | 1 |
| Jiang, HR | 1 |
| Zhong, MZ | 1 |
| Ikeda, E | 1 |
| Kaneko, K | 1 |
| Minashi, K | 1 |
| Nihei, K | 1 |
| Fuse, N | 1 |
| Yano, T | 1 |
| Yoshino, T | 1 |
| Tahara, M | 1 |
| Doi, T | 1 |
| Ohtsu, A | 4 |
| Zambetti, M | 4 |
| Mansutti, M | 2 |
| Gomez, P | 1 |
| Lluch, A | 1 |
| Dittrich, C | 1 |
| Zamagni, C | 1 |
| Ciruelos, E | 1 |
| Pavesi, L | 1 |
| Semiglazov, V | 1 |
| De Benedictis, E | 1 |
| Gaion, F | 1 |
| Bari, M | 1 |
| Morandi, P | 1 |
| Valagussa, P | 5 |
| Luca, G | 1 |
| Dakik, HK | 1 |
| Moskovic, DJ | 1 |
| Carlson, PJ | 1 |
| Tamm, EP | 1 |
| Qiao, W | 1 |
| Wolff, RA | 1 |
| Abbruzzese, JL | 1 |
| Fogelman, DR | 1 |
| Miyata, H | 1 |
| Yasuda, T | 1 |
| Hamano, R | 1 |
| Yamasaki, M | 1 |
| Hou, E | 1 |
| Motoori, M | 1 |
| Shiraishi, O | 1 |
| Tanaka, K | 1 |
| Mori, M | 1 |
| De Bari, B | 1 |
| Lestrade, L | 1 |
| Chekrine, T | 1 |
| Shakir Shakir, I | 1 |
| Ardiet, JM | 1 |
| Chapet, O | 1 |
| Mornex, F | 1 |
| Kim, YJ | 1 |
| Goh, PG | 1 |
| Kim, ES | 1 |
| Lee, SY | 1 |
| Moon, HS | 1 |
| Lee, ES | 1 |
| Sung, JK | 1 |
| Kim, SH | 1 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Kadoyama, K | 1 |
| Miki, I | 2 |
| Tamura, T | 2 |
| Brown, JB | 1 |
| Sakaeda, T | 2 |
| Okuno, Y | 1 |
| Huang, HY | 1 |
| Jiang, ZF | 1 |
| Wang, T | 1 |
| Zhang, SH | 1 |
| Bian, L | 1 |
| Wu, SK | 1 |
| Song, ST | 1 |
| Aguilar-Ponce, JL | 1 |
| Granados-García, M | 1 |
| Cruz López, JC | 1 |
| Maldonado-Magos, F | 1 |
| Alvarez-Avitia, MA | 1 |
| Arrieta, O | 1 |
| González-Ramírez, I | 1 |
| Lara-Cruz, G | 1 |
| Martinez-Juárez, I | 1 |
| Medina-Santillan, R | 1 |
| Castillo-Hernández, C | 1 |
| De la Garza-Salazar, J | 1 |
| Kuwahara, A | 1 |
| Yamamori, M | 1 |
| Nishiguchi, K | 1 |
| Okuno, T | 1 |
| Omatsu, H | 1 |
| Mizuno, S | 1 |
| Hirai, M | 1 |
| Azuma, T | 1 |
| Northfelt, DW | 1 |
| Allred, JB | 1 |
| Hobday, TJ | 1 |
| Rodacker, MW | 1 |
| Lyss, AP | 1 |
| Fitch, TR | 1 |
| Perez, EA | 1 |
| Huang, DZ | 1 |
| Zhuang, ZX | 1 |
| Wan, HP | 1 |
| Zheng, RS | 1 |
| Guo, ZQ | 2 |
| Hu, CH | 1 |
| Wang, ML | 1 |
| Yu, ZH | 1 |
| Meng, JC | 1 |
| Ahn, JH | 1 |
| Kang, YK | 1 |
| Kim, TW | 1 |
| Bahng, H | 1 |
| Chang, HM | 2 |
| Kang, WC | 1 |
| Kim, WK | 1 |
| Lee, JS | 1 |
| Park, JS | 1 |
| Mawdsley, S | 1 |
| Hall, M | 1 |
| Glynne-Jones, R | 1 |
| Matsui, H | 1 |
| Suzuka, K | 1 |
| Iitsuka, Y | 1 |
| Yamazawa, K | 1 |
| Tanaka, N | 1 |
| Mitsuhashi, A | 1 |
| Seki, K | 1 |
| Sekiya, S | 1 |
| Ando, E | 1 |
| Tanaka, M | 3 |
| Yamashita, F | 1 |
| Kuromatsu, R | 1 |
| Yutani, S | 1 |
| Fukumori, K | 1 |
| Sumie, S | 1 |
| Yano, Y | 1 |
| Okuda, K | 1 |
| Sata, M | 1 |
| Bazarbashi, S | 1 |
| Rahal, M | 1 |
| Raja, MA | 1 |
| El Weshi, A | 1 |
| Pai, C | 1 |
| Ezzat, A | 1 |
| Ajarim, D | 1 |
| Memon, M | 1 |
| Al Fadda, M | 1 |
| Mochizuki, F | 2 |
| Kasakura, Y | 1 |
| Yamagata, M | 1 |
| Wakabayashi, K | 1 |
| Kanamori, N | 1 |
| Takayama, T | 1 |
| Leonard, P | 1 |
| Seymour, MT | 1 |
| James, R | 1 |
| Hochhauser, D | 1 |
| Ledermann, JA | 1 |
| Li, Q | 1 |
| Feng, FY | 2 |
| Han, J | 1 |
| Sui, GJ | 1 |
| Zhu, YG | 1 |
| Zhang, ZH | 1 |
| Li, L | 1 |
| Wang, PH | 1 |
| Zhou, MZ | 1 |
| Zhang, YC | 1 |
| Lin, JC | 2 |
| Jan, JS | 2 |
| Hsu, CY | 2 |
| Liang, WM | 1 |
| Jiang, RS | 1 |
| Wang, WY | 1 |
| Okabe, S | 1 |
| Tanami, H | 1 |
| Kuwabara, H | 1 |
| Fukahara, T | 1 |
| Udagawa, M | 1 |
| Ootsukasa, S | 1 |
| Arai, T | 1 |
| Maruyama, S | 1 |
| Murase, N | 1 |
| Yamashita, H | 1 |
| Iwai, T | 1 |
| Yamada, Y | 2 |
| Shimada, Y | 2 |
| Muro, K | 1 |
| Matsumura, Y | 1 |
| Fujita, S | 1 |
| Akasu, T | 1 |
| Moriya, Y | 1 |
| Shirao, K | 3 |
| Tai, CJ | 1 |
| Liu, JH | 4 |
| Chen, WS | 1 |
| Lin, JK | 1 |
| Wang, WS | 4 |
| Yen, CC | 4 |
| Chiou, TJ | 3 |
| Chen, PM | 4 |
| Pervez, H | 1 |
| Potti, A | 1 |
| Mehdi, SA | 1 |
| Ide, H | 1 |
| Eguchi, R | 1 |
| Hayashi, K | 1 |
| Ota, M | 1 |
| Narumiya, K | 1 |
| Takasaki, K | 1 |
| Mitsuhashi, M | 1 |
| WOLBERG, WH | 1 |
| CURRERI, AR | 1 |
| HARTMANN, JR | 1 |
| ORIGENES, ML | 1 |
| MURPHY, ML | 1 |
| SITARZ, A | 1 |
| ERLANDSON, M | 1 |
| SCHELL, HW | 1 |
| EISMAN, SG | 1 |
| RICHARDSON, FM | 1 |
| MOERTEL, CG | 9 |
| REITEMEIER, RJ | 5 |
| HAHN, RG | 9 |
| HURLEY, JD | 1 |
| PAGE, AR | 1 |
| ANSFIELD, FJ | 6 |
| Ura, T | 1 |
| Sasahara, H | 1 |
| Matono, S | 1 |
| Yamana, H | 1 |
| Shirouzu, K | 1 |
| Fujita, H | 2 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Nakata, B | 1 |
| Mitachi, Y | 1 |
| Tsuji, A | 1 |
| Yamamitsu, S | 2 |
| Hirata, K | 2 |
| Shirasaka, T | 3 |
| Hirakawa, K | 2 |
| Cascinu, S | 3 |
| Scartozzi, M | 1 |
| Labianca, R | 1 |
| Catalano, V | 1 |
| Silva, RR | 1 |
| Barni, S | 2 |
| Zaniboni, A | 1 |
| D'Angelo, A | 1 |
| Salvagni, S | 1 |
| Martignoni, G | 1 |
| Beretta, GD | 1 |
| Graziano, F | 2 |
| Berardi, R | 1 |
| Franciosi, V | 1 |
| Miyahara, H | 1 |
| Nario, K | 1 |
| Matsushiro, N | 1 |
| Sasai, H | 1 |
| Kajikawa, H | 1 |
| Matsukura, S | 1 |
| Samejima, R | 1 |
| Hidaka, K | 1 |
| Carlo, WF | 1 |
| Hummer, AJ | 1 |
| Schwartz, L | 1 |
| Sullivan, D | 1 |
| Gonen, M | 1 |
| Jarnagin, W | 1 |
| Fong, Y | 1 |
| Kemeny, N | 1 |
| Park, SH | 1 |
| Bang, SM | 2 |
| Cho, EK | 1 |
| Baek, JH | 1 |
| Oh, JH | 1 |
| Im, SA | 1 |
| Park, YS | 2 |
| Shin, DB | 1 |
| Kimhi, O | 1 |
| Drucker, L | 1 |
| Neumann, A | 1 |
| Shapiro, H | 1 |
| Shapira, J | 1 |
| Yarkoni, S | 1 |
| Lahav, M | 1 |
| Radnay, J | 1 |
| Lishner, M | 1 |
| Mouret-Reynier, MA | 1 |
| Abrial, CJ | 1 |
| Ferrière, JP | 1 |
| Amat, S | 1 |
| Curé, HD | 1 |
| Kwiatkowski, FG | 1 |
| Feillel, VA | 1 |
| Lebouëdec, G | 1 |
| Penault-Llorca, FM | 1 |
| Chollet, PJ | 1 |
| Iguchi, H | 1 |
| Kusuki, M | 1 |
| Nakamura, A | 1 |
| Nishiura, H | 1 |
| Kanazawa, A | 1 |
| Takayama, M | 1 |
| Sunami, K | 1 |
| Yamane, H | 1 |
| Zhou, ZW | 2 |
| Wang, GQ | 2 |
| Pan, ZZ | 2 |
| Li, S | 1 |
| Chen, G | 2 |
| Liao, H | 1 |
| Ji, SH | 1 |
| Lee, J | 1 |
| Lim, DH | 1 |
| Park, BB | 1 |
| Park, KW | 1 |
| Kang, JH | 1 |
| Lee, SH | 1 |
| Park, JO | 1 |
| Kim, K | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Skopelitis, H | 1 |
| Gouveris, P | 1 |
| Kopterides, P | 1 |
| Kopteridis, P | 1 |
| Loukeris, D | 1 |
| Sigala, F | 1 |
| Zorbala-Sypsa, A | 1 |
| Felekouras, E | 1 |
| Papalambros, E | 1 |
| Chiba, N | 1 |
| Yoshioka, T | 1 |
| Kato, S | 2 |
| Takahashi, S | 1 |
| Shibata, H | 2 |
| Sakayori, M | 1 |
| Otsuka, K | 1 |
| Kakudo, Y | 1 |
| Ohori, H | 1 |
| Yamaura, G | 1 |
| Takahashi, M | 1 |
| Yasuda, K | 2 |
| Ishioka, C | 1 |
| Sadahiro, S | 1 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 2 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 4 |
| Mehreen, L | 1 |
| Khanam, A | 1 |
| Asakura, H | 1 |
| Takashima, H | 1 |
| Yokoe, K | 1 |
| Togami, T | 1 |
| Mitani, M | 1 |
| Kiuchi, T | 1 |
| Hosokawa, N | 1 |
| Seo, H | 1 |
| Ohkawa, M | 1 |
| Ito, S | 1 |
| Kodera, Y | 1 |
| Mochizuki, Y | 1 |
| Yamamura, Y | 1 |
| Yang, JW | 1 |
| Chen, YG | 1 |
| Chen, Q | 1 |
| Fan, NF | 1 |
| Cai, XC | 1 |
| Wu, XA | 1 |
| Xu, S | 1 |
| Lu, X | 1 |
| Zhang, YH | 1 |
| Ouyang, XN | 1 |
| Wilkowski, R | 1 |
| Thoma, M | 1 |
| Bruns, C | 1 |
| Dühmke, E | 1 |
| Heinemann, V | 1 |
| Tagaya, N | 1 |
| Nakagawa, A | 1 |
| Mori, S | 1 |
| Hamada, K | 1 |
| Suzuki, N | 1 |
| Kubota, K | 1 |
| Takahari, D | 2 |
| Tsuji, Y | 2 |
| Sagawa, T | 1 |
| Honda, K | 3 |
| Sumiyoshi, T | 2 |
| Yoshizaki, N | 2 |
| Kuroiwa, G | 1 |
| Kondo, H | 2 |
| Kim, JS | 2 |
| Cho, MJ | 1 |
| Yoon, WH | 1 |
| Song, KS | 1 |
| Ohta, K | 1 |
| Dohden, K | 1 |
| Morishita, M | 1 |
| Hattori, M | 1 |
| Hosokawa, O | 1 |
| Morita, M | 1 |
| Kaizaki, Y | 1 |
| Kiya, T | 1 |
| Felici, A | 1 |
| Loos, WJ | 1 |
| Verweij, J | 2 |
| Cirillo, I | 1 |
| de Bruijn, P | 1 |
| Nooter, K | 1 |
| Mathijssen, RH | 1 |
| de Jonge, MJ | 1 |
| Matsuda, T | 1 |
| Ogino, K | 1 |
| Hiroyoshi, M | 1 |
| Itoh, T | 1 |
| Toyama, H | 1 |
| Kawai, Y | 1 |
| Makita, D | 1 |
| Tsunemi, K | 1 |
| Moritomo, H | 1 |
| Okusaka, T | 1 |
| Ishii, H | 1 |
| Funakoshi, A | 1 |
| Furuse, J | 1 |
| Sumii, T | 1 |
| Zhang, P | 1 |
| Wu, LY | 2 |
| Hu, Y | 1 |
| Liu, JW | 1 |
| Gao, YJ | 1 |
| Guan, XQ | 1 |
| Nan, KJ | 1 |
| Suo, AL | 1 |
| Wang, XW | 1 |
| Zhang, MH | 1 |
| Zhang, WD | 1 |
| Li, CW | 1 |
| Zhao, JB | 1 |
| Eguchi, T | 1 |
| Sano, M | 2 |
| Tokuda, Y | 1 |
| Noguchi, S | 2 |
| Aogi, K | 1 |
| Saeki, T | 2 |
| Tabei, T | 2 |
| Hatake, K | 1 |
| Fujii, H | 1 |
| Jiang, Y | 1 |
| Qiu, XH | 1 |
| Yang, YX | 1 |
| Zhang, SQ | 1 |
| Chen, ZM | 1 |
| Tsubono, M | 2 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Deguchi, Y | 1 |
| Sonoda, K | 1 |
| Mattison, LK | 1 |
| Fourie, J | 1 |
| Desmond, RA | 1 |
| Modak, A | 1 |
| Saif, MW | 1 |
| Diasio, RB | 2 |
| Inaji, H | 1 |
| Sakai, K | 1 |
| Oka, T | 1 |
| Ozawa, K | 1 |
| Saito, Y | 1 |
| Senoo, T | 1 |
| Taguchi, T | 6 |
| Terasawa, T | 1 |
| Nakao, K | 1 |
| Mori, T | 1 |
| Koyama, H | 1 |
| Oshima, A | 1 |
| Katori, H | 1 |
| Tsukuda, M | 1 |
| Gaffney, DK | 1 |
| Winter, K | 1 |
| Dicker, AP | 1 |
| Miller, B | 1 |
| Eifel, PJ | 2 |
| Ryu, J | 1 |
| Avizonis, V | 1 |
| Fromm, M | 1 |
| Greven, K | 1 |
| Fukuhara, T | 1 |
| Kojima, Y | 1 |
| Tanaka, H | 1 |
| Kushihata, F | 1 |
| Minamide, J | 1 |
| Aoyama, N | 1 |
| Takada, K | 1 |
| Oota, Y | 1 |
| Tanaka, S | 1 |
| Tsushima, T | 1 |
| Ohura, K | 1 |
| Wang, XX | 1 |
| Zhou, ZM | 1 |
| Yuan, ZY | 1 |
| Zhang, DS | 1 |
| Shi, YX | 1 |
| Jiang, WQ | 1 |
| Lu, ZH | 1 |
| Fang, YJ | 1 |
| Wu, XJ | 1 |
| Li, LR | 1 |
| Ding, PR | 1 |
| Liu, K | 1 |
| Wang, GB | 1 |
| Cheng, B | 1 |
| Qiu, DB | 1 |
| Minami, K | 1 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Suzuki, T | 2 |
| Miyahara, E | 1 |
| Noso, Y | 1 |
| Larsen, S | 1 |
| Serup-Hansen, E | 1 |
| Andersen, LJ | 1 |
| Lindeløv, B | 1 |
| McCulloch, T | 1 |
| Adimi, P | 1 |
| Bastholt, L | 1 |
| Maruoka, Y | 2 |
| Ogiuchi, Y | 2 |
| Ogiuchi, H | 2 |
| Park, JY | 1 |
| Ahn, SH | 1 |
| Yoon, YJ | 1 |
| Kim, JK | 1 |
| Lee, HW | 1 |
| Lee, DY | 1 |
| Chon, CY | 1 |
| Moon, YM | 1 |
| Han, KH | 1 |
| Bezerra, DP | 1 |
| de Castro, FO | 1 |
| Alves, AP | 1 |
| Pessoa, C | 1 |
| de Moraes, MO | 1 |
| Silveira, ER | 1 |
| Lima, MA | 1 |
| Elmiro, FJ | 1 |
| de Alencar, NM | 1 |
| Mesquita, RO | 1 |
| Lima, MW | 1 |
| Costa-Lotufo, LV | 1 |
| Schneider, BJ | 1 |
| El-Rayes, B | 1 |
| Muler, JH | 1 |
| Philip, PA | 1 |
| Kalemkerian, GP | 1 |
| Griffith, KA | 1 |
| Zalupski, MM | 2 |
| Shitara, K | 1 |
| Munakata, M | 1 |
| Muto, O | 1 |
| Kasai, M | 1 |
| Okada, R | 1 |
| Mitobe, S | 1 |
| Sakata, Y | 3 |
| Xie, FY | 1 |
| Qi, SN | 1 |
| Hu, WH | 1 |
| Zou, GR | 1 |
| Peng, M | 1 |
| Li, JS | 1 |
| Gong, JF | 1 |
| Di, LJ | 1 |
| Torres, MA | 1 |
| Jhingran, A | 1 |
| Thames, HD | 1 |
| Levenback, CF | 1 |
| Bodurka, DC | 1 |
| Ramondetta, LM | 1 |
| Bai, P | 1 |
| Li, XG | 1 |
| Ma, SK | 1 |
| Zhang, WH | 1 |
| Mell, LK | 1 |
| Schomas, DA | 1 |
| Salama, JK | 1 |
| Devisetty, K | 1 |
| Aydogan, B | 1 |
| Miller, RC | 1 |
| Jani, AB | 1 |
| Kindler, HL | 1 |
| Mundt, AJ | 1 |
| Roeske, JC | 1 |
| Chmura, SJ | 1 |
| Gnad-Vogt, U | 1 |
| Schultheis, B | 1 |
| Ezzeldin, HH | 1 |
| Marx, C | 1 |
| Schaeffeler, E | 1 |
| Dippon, J | 1 |
| Kerb, R | 1 |
| Blievernicht, J | 1 |
| Fischer, J | 1 |
| Hofmann, U | 1 |
| Bokemeyer, C | 2 |
| Eichelbaum, M | 1 |
| Hui, R | 1 |
| Zhang, M | 1 |
| Hao, XM | 1 |
| Benz, C | 1 |
| Tillis, T | 1 |
| Tattelman, E | 1 |
| Cadman, E | 1 |
| Kemeny, NE | 1 |
| Ahmed, T | 1 |
| Michaelson, RA | 1 |
| Harper, HD | 1 |
| Yip, LC | 1 |
| Togni, P | 1 |
| Sessa, C | 1 |
| Varini, M | 1 |
| Cavalli, F | 1 |
| Herrmann, R | 1 |
| Spehn, J | 1 |
| Beyer, JH | 1 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 1 |
| Abel, U | 1 |
| Browman, GP | 1 |
| Archibald, SD | 1 |
| Young, JE | 1 |
| Hryniuk, WM | 1 |
| Russell, R | 1 |
| Kiehl, K | 1 |
| Levine, MN | 1 |
| Tormey, DC | 4 |
| Weinberg, VE | 1 |
| Leone, LA | 1 |
| Glidewell, OJ | 1 |
| Perloff, M | 1 |
| Kennedy, BJ | 2 |
| Cortes, E | 1 |
| Silver, RT | 1 |
| Weiss, RB | 3 |
| Aisner, J | 1 |
| Kasajima, T | 1 |
| Yamakawa, M | 1 |
| Maeda, K | 1 |
| Matsuda, M | 1 |
| Dobashi, M | 1 |
| Imai, Y | 2 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Beck, TM | 1 |
| Curtis, PW | 1 |
| Woodard, DA | 1 |
| Hart, NE | 1 |
| Smith, CE | 1 |
| Kish, JA | 2 |
| Weaver, A | 2 |
| Jacobs, J | 2 |
| Cummings, G | 1 |
| Al-Sarraf, M | 5 |
| Minshull, M | 1 |
| Gardner, ML | 1 |
| Vogl, SE | 3 |
| Engstrom, PF | 2 |
| Pinnamaneni, K | 1 |
| Yap, HY | 1 |
| Buzdar, AU | 1 |
| Distefano, A | 1 |
| Blumenschein, GR | 2 |
| Fornasiero, A | 1 |
| Cartei, G | 2 |
| Daniele, O | 1 |
| Fosser, V | 1 |
| Fiorentino, MV | 1 |
| Banerjee, TK | 1 |
| Hoehn, JL | 1 |
| Greenlaw, RH | 1 |
| Jacoby, C | 1 |
| Windschitl, H | 1 |
| Scott, M | 1 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 2 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Tashiro, K | 1 |
| Machida, T | 1 |
| Masuda, F | 1 |
| Ohishi, Y | 1 |
| Waibel, PJ | 1 |
| Jungi, WF | 1 |
| Senn, HJ | 1 |
| Decker, DA | 1 |
| Drelichman, A | 1 |
| Hoschner, J | 1 |
| Kinzie, J | 1 |
| Loh, JJ | 1 |
| Kreuter, J | 1 |
| Hartmann, HR | 1 |
| Kotake, T | 1 |
| Usami, M | 1 |
| Miki, T | 1 |
| Kuroda, M | 1 |
| Obata, K | 1 |
| Osafune, M | 1 |
| Fujioka, H | 1 |
| Takasugi, Y | 1 |
| Lee, YT | 2 |
| Shamberger, RC | 1 |
| Devereux, DF | 1 |
| Brennan, MF | 1 |
| Chang, YC | 1 |
| Falkson, G | 2 |
| Crowley, J | 1 |
| Cummings, BJ | 1 |
| Rider, WD | 1 |
| Harwood, AR | 1 |
| Keane, TJ | 1 |
| Thomas, GM | 1 |
| Erlichman, C | 1 |
| Fine, S | 1 |
| Marzetti, L | 1 |
| Marcellini, G | 1 |
| Midulla, C | 1 |
| Bedwinek, JM | 1 |
| Ratkin, GA | 1 |
| Philpott, GW | 1 |
| Wallack, M | 1 |
| Perez, CA | 1 |
| Vaughn, CB | 4 |
| Maniscalco-Greb, E | 1 |
| Lockhard, C | 1 |
| Groshko, G | 2 |
| Enochs, K | 2 |
| Duffin, H | 1 |
| Demitrish, M | 1 |
| Dalley, DN | 1 |
| Levi, JA | 1 |
| Aroney, RS | 1 |
| Chlebowski, RT | 2 |
| Silverberg, I | 1 |
| Pajak, T | 1 |
| Weiner, J | 1 |
| Kardinal, C | 1 |
| Bateman, JR | 3 |
| Lanham, R | 2 |
| Kaplan, BH | 2 |
| Solan, A | 1 |
| Berenzweig, M | 1 |
| Richard, J | 1 |
| Ahmann, DL | 2 |
| O'Fallon, JR | 2 |
| Scanlon, PW | 1 |
| Payne, WS | 1 |
| Bisel, HF | 2 |
| Edmonson, JH | 1 |
| Frytak, S | 1 |
| Ingle, JN | 2 |
| Rubin, J | 3 |
| Creagan, ET | 1 |
| Martin, DS | 2 |
| Stolfi, RL | 1 |
| Sawyer, RC | 1 |
| Spiegelman, S | 1 |
| Young, CW | 1 |
| Pugh, RP | 1 |
| Weiner, JM | 1 |
| Gasser, RW | 1 |
| Schmalzl, F | 1 |
| Martino, S | 2 |
| Samal, B | 3 |
| Smith, FP | 2 |
| Hoth, DF | 1 |
| Levin, B | 1 |
| Karlin, DA | 1 |
| MacDonald, JS | 4 |
| Woolley, PV | 2 |
| Schein, PS | 3 |
| Smythe, T | 1 |
| Ueno, W | 2 |
| Hoth, D | 1 |
| Smith, F | 2 |
| Boiron, M | 1 |
| Gisselbrecht, C | 1 |
| Brunet, R | 2 |
| Lagarde, C | 1 |
| Callari, A | 1 |
| Gebbia, V | 2 |
| Testa, A | 2 |
| Cusimano, MP | 1 |
| Cipolla, C | 1 |
| Amato, C | 1 |
| Cannata, G | 1 |
| Latteri, MA | 1 |
| Garascia, C | 1 |
| Gebbia, N | 2 |
| Emerson, SS | 1 |
| Greenhouse, JB | 1 |
| Wasserman, L | 1 |
| Kohno, N | 1 |
| Ichikawa, G | 1 |
| Inuyama, Y | 1 |
| Kawaida, M | 1 |
| Ohnuma, T | 1 |
| Hill, M | 1 |
| Norman, A | 1 |
| Cunningham, D | 2 |
| Findlay, M | 1 |
| Watson, M | 1 |
| Nicolson, V | 1 |
| Webb, A | 1 |
| Middleton, G | 1 |
| Ahmed, F | 1 |
| Hickish, T | 1 |
| Shuin, T | 1 |
| Kubota, Y | 1 |
| Masuda, M | 1 |
| Yao, M | 1 |
| Hosaka, M | 1 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Aquino, A | 1 |
| Gonnelli, S | 1 |
| Sugano, K | 1 |
| Ota, K | 2 |
| Kurihara, M | 3 |
| Akazawa, S | 2 |
| Ogawa, M | 1 |
| Tominaga, T | 2 |
| Konishi, T | 1 |
| Marshall, ME | 1 |
| Tangen, CM | 1 |
| Berenberg, JL | 1 |
| Balcerzak, SP | 1 |
| Brown, T | 1 |
| Takeda, S | 1 |
| Ohta, J | 1 |
| Abe, T | 2 |
| Ohtani, T | 1 |
| Yonemura, Y | 1 |
| Ohno, T | 1 |
| Hirabayashi, N | 1 |
| Nakano, S | 1 |
| Konishi, K | 1 |
| Yabushita, K | 1 |
| Ota, J | 1 |
| Takashima, S | 2 |
| Kikkawa, N | 1 |
| Yasutomi, M | 1 |
| Sowa, M | 2 |
| Stein, BN | 1 |
| Petrelli, NJ | 2 |
| Douglass, HO | 3 |
| Driscoll, DL | 1 |
| Arcangeli, G | 1 |
| Tomioka, K | 1 |
| Mizuno, Y | 1 |
| Sato, F | 1 |
| Yamagata, T | 1 |
| Nagakawa, Y | 1 |
| Kobari, Y | 1 |
| Iwai, S | 1 |
| Orlandi, F | 1 |
| Caraci, P | 1 |
| Puligheddu, B | 1 |
| Pivano, G | 1 |
| Mans, DR | 1 |
| Scaletzky, A | 1 |
| Becker, D | 1 |
| de Oliveria, JR | 1 |
| Pinheiro, CM | 1 |
| Bittar, C | 1 |
| Ferreira Filho, A | 1 |
| Machado, VL | 1 |
| Ritt, JL | 1 |
| Jung, FA | 1 |
| Yoshida, S | 3 |
| Saito, H | 1 |
| Seki, S | 1 |
| Morise, K | 2 |
| Shinoda, M | 1 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Ina, K | 1 |
| Kaneko, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Oka, Y | 1 |
| Nakazato, H | 1 |
| Koike, A | 1 |
| Saji, S | 1 |
| Sakamoto, J | 1 |
| Nakai, Y | 1 |
| Furuse, K | 1 |
| Ohta, M | 1 |
| Yamaguchi, Y | 1 |
| Asakawa, M | 1 |
| Fukuoka, M | 1 |
| Yoshida, K | 1 |
| Niitani, H | 1 |
| Pinnarò, P | 1 |
| Cercato, MC | 1 |
| Giannarelli, D | 1 |
| Carlini, P | 1 |
| Del Vecchio, MR | 1 |
| Impiombato, FA | 1 |
| Marzetti, F | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Gasparini, G | 1 |
| Caffo, O | 1 |
| Frontini, L | 1 |
| Testolin, A | 1 |
| Guglielmi, RB | 1 |
| Ambrosini, G | 1 |
| Stöger, H | 2 |
| Bauernhofer, T | 1 |
| Schmid, M | 2 |
| Ploner, F | 1 |
| Moser, R | 1 |
| Derstvenscheg, E | 1 |
| Steindorfer, P | 2 |
| Wilders-Truschnig, M | 1 |
| Kuss, I | 1 |
| Samonigg, H | 2 |
| Ravikumar, TS | 1 |
| Pizzorno, G | 1 |
| Bodden, W | 1 |
| Marsh, J | 1 |
| Strair, R | 1 |
| Pollack, J | 1 |
| Hendler, R | 1 |
| Hanna, J | 1 |
| D'Andrea, E | 1 |
| Leyvraz, S | 1 |
| Pasche, P | 1 |
| Bauer, J | 1 |
| Bernasconi, S | 1 |
| Monnier, P | 1 |
| Scheithauer, W | 2 |
| Depisch, D | 2 |
| Kornek, G | 2 |
| Pidlich, J | 2 |
| Rosen, H | 2 |
| Karall, M | 1 |
| Prochaska, M | 1 |
| Ernst, A | 1 |
| Sebesta, C | 1 |
| Eckhardt, S | 1 |
| Stahl, M | 2 |
| Wilke, H | 1 |
| Meyer, HJ | 1 |
| Preusser, P | 1 |
| Berns, T | 1 |
| Fink, U | 1 |
| Achterrath, W | 1 |
| Knipp, H | 1 |
| Harstrick, A | 1 |
| Berger, M | 1 |
| Tsushima, K | 1 |
| Saito, S | 1 |
| Ito, T | 1 |
| Sugimoto, N | 1 |
| Ogasawara, H | 1 |
| Tamura, Y | 1 |
| Moriya, N | 1 |
| Komatsu, Y | 1 |
| Carmo-Pereira, J | 1 |
| Costa, FO | 1 |
| Henriques, E | 1 |
| Ardizzoni, A | 1 |
| Venturini, M | 1 |
| Sertoli, MR | 1 |
| Giannessi, PG | 1 |
| Brema, F | 1 |
| Danova, M | 2 |
| Testore, F | 1 |
| Mariani, GL | 1 |
| Pennucci, MC | 1 |
| Queirolo, P | 1 |
| Tomio, L | 1 |
| Zorat, PL | 1 |
| Paccagnella, A | 1 |
| Segati, R | 1 |
| Loreggian, L | 1 |
| Lora, O | 1 |
| Friso, ML | 1 |
| Chiarion-Sileni, V | 1 |
| Favaretto, A | 1 |
| Fede, A | 1 |
| Roelofs, EJ | 1 |
| Wagener, DJ | 1 |
| Conroy, T | 1 |
| Burghouts, JT | 1 |
| Fickers, M | 1 |
| de Graeff, A | 1 |
| Lalisang, F | 1 |
| Paillot, B | 1 |
| Uchino, J | 1 |
| Une, Y | 1 |
| Sato, Y | 1 |
| Gondo, H | 1 |
| Nakajima, Y | 1 |
| Sato, N | 1 |
| Colleoni, M | 1 |
| Rosso, R | 1 |
| Sobrero, A | 1 |
| Amadori, D | 1 |
| Comella, G | 1 |
| Marangolo, M | 1 |
| Scanni, A | 1 |
| Lorusso, V | 1 |
| Calabresi, F | 1 |
| Sinnige, HA | 1 |
| Buter, J | 1 |
| de Vries, EG | 2 |
| Uges, DR | 1 |
| Roenhorst, HW | 1 |
| Verschueren, RC | 1 |
| Sleijfer, DT | 2 |
| Willemse, PH | 2 |
| Mulder, NH | 2 |
| van Groeningen, CJ | 2 |
| Peters, GJ | 4 |
| Pinedo, HM | 2 |
| Boku, N | 2 |
| Fujii, T | 1 |
| Miyata, Y | 1 |
| Hosokawa, K | 1 |
| Koba, I | 1 |
| Shimizu, W | 1 |
| Ogino, T | 1 |
| Baker, LH | 2 |
| Yagihashi, A | 1 |
| Sasaki, K | 1 |
| Zalcberg, JR | 1 |
| Rath, U | 1 |
| Olver, I | 1 |
| Van Cutsem, E | 1 |
| Svensson, C | 1 |
| Harper, P | 1 |
| Kerr, D | 1 |
| Perez-Manga, G | 1 |
| Beuzeboc, P | 1 |
| Pierga, JY | 1 |
| Lyonnet, DS | 1 |
| Couturier, J | 1 |
| Pouillart, P | 1 |
| Galandiuk, S | 1 |
| Wrightson, W | 1 |
| Marr, L | 1 |
| Myers, S | 1 |
| LaRocca, RV | 1 |
| Majello, E | 1 |
| Pezzella, G | 1 |
| Giuseppe, S | 1 |
| Giotta, F | 1 |
| Riccardi, F | 1 |
| Fortunato, S | 1 |
| Colucci, G | 1 |
| Nishinakamura, R | 1 |
| Miyajima, A | 1 |
| Mee, PJ | 1 |
| Tybulewicz, VL | 1 |
| Murray, R | 1 |
| Del Ferro, E | 1 |
| Ligi, M | 1 |
| Catalano, G | 2 |
| Miyauchi, S | 1 |
| Imaoka, T | 1 |
| Okada, T | 1 |
| Motoyama, M | 1 |
| Kawaguchi, T | 1 |
| Akiyama, H | 1 |
| Odomi, M | 1 |
| Fujinami, K | 1 |
| Ikeda, I | 1 |
| Miura, T | 1 |
| Kondo, I | 1 |
| Schwartz, GK | 1 |
| Christman, K | 1 |
| Saltz, L | 1 |
| Casper, E | 1 |
| Quan, V | 1 |
| Bertino, J | 1 |
| Colofiore, J | 1 |
| Kelsen, D | 1 |
| Cascino, TL | 1 |
| Veeder, MH | 2 |
| Buckner, JC | 1 |
| Wiesenfeld, M | 1 |
| Levitt, R | 1 |
| Kuross, SA | 1 |
| Morton, RF | 2 |
| Scheithauer, BW | 1 |
| Fleming, GF | 1 |
| O'Brien, SM | 1 |
| Hoffman, PC | 1 |
| Vokes, EE | 1 |
| Vogelzang, NJ | 1 |
| Schilsky, RL | 1 |
| Waggoner, SE | 1 |
| Ratain, MJ | 2 |
| Marczell, A | 1 |
| Salem, G | 1 |
| Karner, J | 1 |
| Kovats, E | 1 |
| Burger, D | 1 |
| Greiner, R | 1 |
| Schneeweiss, B | 1 |
| Raderer, M | 1 |
| Laurenz, JC | 1 |
| Hadjisavas, M | 1 |
| Chovanic, GW | 1 |
| Bazer, FW | 1 |
| Kardinal, CG | 3 |
| Suman, VJ | 1 |
| Schaefer, PL | 1 |
| Kirschling, RJ | 1 |
| Mailliard, JA | 2 |
| Tepper, JE | 1 |
| Petroni, GR | 1 |
| Hollis, D | 1 |
| Cooke, E | 1 |
| Benson, AB | 1 |
| Cummings, B | 1 |
| Gunderson, LL | 1 |
| Martenson, JA | 1 |
| Aranda, E | 1 |
| Cervantes, A | 1 |
| Antón-Torres, A | 1 |
| Massutí, T | 1 |
| Fernández-Martos, C | 1 |
| Díaz-Rubio, E | 1 |
| Wolf, MK | 1 |
| Schellhammer, PF | 1 |
| Hussain, MH | 1 |
| Einstein, AB | 1 |
| Crawford, ED | 1 |
| Demicheli, R | 1 |
| De Candis, D | 1 |
| Antonelli, G | 1 |
| Giacobone, A | 1 |
| Terenziani, M | 1 |
| Laffranchi, A | 1 |
| Garbagnati, F | 1 |
| Biasi, S | 1 |
| Bonadonna, G | 5 |
| Iop, A | 1 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Sibau, AM | 1 |
| Tung, SL | 2 |
| Hsieh, RK | 2 |
| Tokumaru, Y | 1 |
| Imanishi, Y | 1 |
| Kanke, M | 1 |
| Kanzaki, J | 1 |
| Ohno, Y | 1 |
| Ollivier, S | 1 |
| Fonck, M | 1 |
| Bécouarn, Y | 1 |
| Merlano, M | 1 |
| Benasso, M | 1 |
| Numico, GM | 1 |
| Santelli, A | 1 |
| Ameli, F | 1 |
| Blengio, F | 1 |
| Ricci, I | 1 |
| Rosso, M | 1 |
| Cardarelli, N | 1 |
| Marcellini, M | 1 |
| Giordani, P | 1 |
| Menichetti, ET | 1 |
| Kikuyama, S | 1 |
| Inada, T | 1 |
| Miyakita, M | 1 |
| Fan, FS | 2 |
| Ishikawa, K | 1 |
| Shimoda, K | 1 |
| Shiraishi, N | 1 |
| Adachi, Y | 1 |
| Kitano, S | 1 |
| Darnton, SJ | 1 |
| Ferry, DR | 1 |
| Cullen, MH | 1 |
| Casson, AG | 1 |
| Ikeda, T | 1 |
| Adachi, I | 1 |
| Ogita, M | 1 |
| Aoyama, H | 1 |
| Ando, J | 1 |
| Enomoto, K | 1 |
| Kanda, K | 1 |
| Fukutomi, T | 1 |
| Shimoyama, M | 1 |
| Schröder, CP | 1 |
| Hospers, GA | 1 |
| van der Graaf, WT | 1 |
| Clarke, J | 1 |
| Edwards, B | 1 |
| Srpek, L | 1 |
| Regester, G | 1 |
| Itoh, Y | 1 |
| Fuwa, N | 1 |
| Matsumoto, A | 1 |
| Asano, A | 1 |
| Sasaoka, M | 1 |
| Kvinnsland, S | 1 |
| Poikonen, P | 2 |
| Saarto, T | 1 |
| Lundin, J | 1 |
| Joensuu, H | 2 |
| Yamashita, Y | 1 |
| Ohira, M | 1 |
| Chung, YS | 1 |
| Joseph, CD | 1 |
| Praveenkumar, V | 1 |
| Kuttan, G | 1 |
| Kuttan, R | 1 |
| Heo, DS | 1 |
| Lee, KH | 1 |
| Byun, JH | 1 |
| Noh, DY | 1 |
| Choe, KJ | 1 |
| Bang, YJ | 1 |
| Kim, SR | 1 |
| Kim, NK | 1 |
| Domenge, C | 1 |
| Hill, C | 1 |
| Lefebvre, JL | 1 |
| De Raucourt, D | 1 |
| Rhein, B | 1 |
| Wibault, P | 1 |
| Marandas, P | 1 |
| Coche-Dequeant, B | 1 |
| Stromboni-Luboinski, M | 1 |
| Sancho-Garnier, H | 1 |
| Luboinski, B | 1 |
| Yang, MH | 1 |
| Chang, YH | 1 |
| Chen, KK | 1 |
| Choi, EK | 1 |
| Kim, SB | 1 |
| Park, SI | 1 |
| Kim, DK | 1 |
| Song, HY | 1 |
| Jung, HY | 1 |
| Min, YI | 1 |
| Sekikawa, K | 1 |
| Anzai, K | 1 |
| Ishihata, R | 1 |
| Yamaki, T | 1 |
| Ohki, S | 1 |
| Kimijima, I | 1 |
| Takenoshita, S | 1 |
| Raida, M | 1 |
| Schwabe, W | 1 |
| Häusler, P | 1 |
| Van Kuilenburg, AB | 2 |
| Van Gennip, AH | 1 |
| Behnke, D | 1 |
| Höffken, K | 1 |
| Valentini, V | 1 |
| Coco, C | 1 |
| Cellini, N | 1 |
| Picciocchi, A | 1 |
| Fares, MC | 1 |
| Rosetto, ME | 1 |
| Mantini, G | 1 |
| Morganti, AG | 1 |
| Barbaro, B | 1 |
| Cogliandolo, S | 1 |
| Nuzzo, G | 1 |
| Tedesco, M | 1 |
| Ambesi-Impiombato, F | 1 |
| Cosimelli, M | 1 |
| Rotman, M | 1 |
| Nagashima, F | 1 |
| Muto, M | 1 |
| Shinkai, T | 1 |
| Wenzel, C | 1 |
| Locker, GJ | 1 |
| Schmidinger, M | 1 |
| Mader, R | 1 |
| Kramer, G | 1 |
| Marberger, M | 1 |
| Rauchenwald, M | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Sakon, M | 1 |
| Nagano, H | 1 |
| Dono, K | 1 |
| Nakamori, S | 1 |
| Umeshita, K | 1 |
| Yamada, A | 2 |
| Kawata, S | 1 |
| Iijima, S | 1 |
| Monden, M | 1 |
| Vermes, A | 1 |
| Guchelaar, HJ | 1 |
| Dankert, J | 1 |
| Hoshino, M | 1 |
| Nishihara, N | 1 |
| Okamoto, T | 1 |
| Fukada, K | 1 |
| Kuwazawa, T | 1 |
| Melchart, D | 1 |
| Clemm, C | 1 |
| Weber, B | 1 |
| Draczynski, T | 1 |
| Worku, F | 1 |
| Linde, K | 1 |
| Weidenhammer, W | 1 |
| Wagner, H | 1 |
| Saller, R | 1 |
| Innocenti, F | 1 |
| Yamazaki, S | 1 |
| Morita, T | 1 |
| Endo, H | 1 |
| Hamamoto, T | 1 |
| Baba, M | 1 |
| Joichi, Y | 1 |
| Kaneko, S | 1 |
| Okada, Y | 1 |
| Okuyama, T | 1 |
| Nishino, H | 1 |
| Tokue, A | 1 |
| Samuels, ML | 1 |
| Holoye, PY | 1 |
| Johnson, DE | 1 |
| Lichinitser, MR | 1 |
| Perevodchikova, NI | 1 |
| Garin, AM | 1 |
| Asserkritova, IV | 1 |
| Vaarik, GKh | 1 |
| Fisher, B | 1 |
| Glass, A | 1 |
| Redmond, C | 1 |
| Fisher, ER | 1 |
| Barton, B | 1 |
| Such, E | 1 |
| Carbone, P | 1 |
| Economou, S | 1 |
| Foster, R | 1 |
| Frelick, R | 1 |
| Lerner, H | 1 |
| Levitt, M | 1 |
| Margolese, R | 1 |
| MacFarlane, J | 1 |
| Plotkin, D | 1 |
| Volk, H | 1 |
| Foster, RS | 1 |
| Rossi, A | 3 |
| Banfi, A | 1 |
| Veronesi, U | 3 |
| Diggs, CH | 1 |
| Wiernik, PH | 1 |
| Smyth, AC | 1 |
| Blumenson, LE | 1 |
| Bross, ID | 2 |
| White, LA | 1 |
| Perry, MC | 1 |
| Carey, RW | 1 |
| Fox, RM | 1 |
| Woods, RL | 1 |
| Tattersall, HN | 1 |
| Brodie, GW | 1 |
| Hortobagyi, GN | 1 |
| Gutterman, JU | 1 |
| Buzdar, A | 1 |
| Burgess, MA | 1 |
| Richman, SP | 1 |
| Tashima, CK | 1 |
| Schwarz, M | 1 |
| Hersh, EM | 1 |
| Tranum, B | 1 |
| Hoogstraten, B | 2 |
| Kennedy, A | 1 |
| Thigpen, T | 2 |
| Rivkin, S | 1 |
| Palmer, RL | 1 |
| Costanzi, J | 1 |
| Tucker, WG | 1 |
| Wilson, H | 1 |
| Maloney, TR | 1 |
| Rubens, RD | 1 |
| Knight, RK | 1 |
| Hayward, JL | 1 |
| Cedermark, BJ | 2 |
| Didolkar, MS | 1 |
| Elias, EG | 1 |
| Kaufman, JH | 1 |
| Mittelman, A | 1 |
| Posey, LE | 1 |
| Morgan, LR | 1 |
| Tejada, F | 1 |
| Eisenberger, MA | 1 |
| Broder, LA | 1 |
| Cohen, MH | 1 |
| Simon, R | 1 |
| Scialla, SJ | 1 |
| Miskoff, RA | 1 |
| George, SL | 1 |
| Rivkin, SE | 1 |
| Costanzi, JJ | 1 |
| Bonnet, JD | 1 |
| Braine, H | 1 |
| Merrin, C | 1 |
| Etra, W | 1 |
| Wajsman, Z | 1 |
| Baumgartner, G | 1 |
| Murphy, G | 1 |
| Muss, HB | 1 |
| Lokich, JJ | 2 |
| Frei, E | 1 |
| Pitman, SW | 1 |
| Skarin, AT | 1 |
| Hisadome, M | 1 |
| Fukuda, T | 1 |
| Terasawa, M | 1 |
| Oe, T | 1 |
| Takahata, H | 1 |
| Goto, K | 1 |
| Tsuru, S | 1 |
| Nomoto, K | 3 |
| Miura, S | 1 |
| Takimoto, H | 1 |
| Yoshikai, Y | 2 |
| Kumazawa, Y | 1 |
| van der Wilt, CL | 2 |
| van Laar, JA | 2 |
| Gyergyay, F | 1 |
| Smid, K | 1 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
| Miyazaki, H | 1 |
| Takeda, Y | 1 |
| Takeo, S | 1 |
| Nio, Y | 1 |
| Shiraishi, T | 1 |
| Morimoto, H | 1 |
| Tseng, CC | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Fukumoto, M | 1 |
| Tobe, T | 1 |
| Amrein, PC | 1 |
| Fabian, RL | 1 |
| Weh, HJ | 1 |
| Platz, D | 1 |
| Braumann, D | 1 |
| Buggisch, P | 1 |
| Eckardt, N | 1 |
| Schmiegel, WH | 1 |
| Drescher, S | 1 |
| Kleeberg, UR | 1 |
| Müllerleile, U | 1 |
| Crone-Munzebrock, W | 1 |
| Pyrhönen, SO | 1 |
| Kouri, MO | 1 |
| Aitini, E | 1 |
| Cavazzini, G | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Rivera, A | 1 |
| Togliani, B | 1 |
| Di Marco, A | 1 |
| Smerieri, F | 1 |
| Laurie, JA | 1 |
| Therneau, TM | 1 |
| Patel, SR | 1 |
| Windschitl, HE | 1 |
| Twito, DI | 1 |
| Krook, JE | 2 |
| Schöber, C | 1 |
| Wilke, HJ | 1 |
| Schmoll, HJ | 1 |
| Poliwoda, H | 1 |
| Lindeman, GJ | 1 |
| Boyages, J | 1 |
| Driessen, C | 1 |
| Langlands, AO | 1 |
| Flaherty, L | 1 |
| Wozniak, A | 1 |
| Redman, B | 1 |
| Kraut, M | 1 |
| Heilbrun, L | 1 |
| Valdivieso, M | 1 |
| Langer, CJ | 1 |
| Walczak, J | 1 |
| Levy, MH | 1 |
| Padavic-Shaller, K | 1 |
| Hudes, GR | 1 |
| Comis, RL | 1 |
| Tohnai, I | 1 |
| Kawabe, Y | 1 |
| Nakashima, T | 1 |
| Yamagiwa, M | 1 |
| Mizuno, A | 1 |
| Mineda, H | 1 |
| Anderson, H | 1 |
| Scarffe, JH | 1 |
| Ranson, M | 1 |
| Kamthan, AG | 1 |
| Dougal, M | 1 |
| Russell, SA | 1 |
| Wilkinson, MJ | 1 |
| Ostick, DG | 1 |
| Kasparek, AK | 1 |
| Dusleag, J | 1 |
| Pfeiffer, K | 1 |
| Smola, M | 1 |
| Lechner, P | 1 |
| Tsukikawa, S | 1 |
| Satoh, T | 1 |
| Morikubo, M | 1 |
| Komoriyama, H | 1 |
| Hagiwara, M | 1 |
| Kanasugi, K | 1 |
| Yamaguchi, S | 1 |
| Wieand, HS | 2 |
| Schutt, AJ | 6 |
| Foley, JF | 1 |
| Norris, BD | 1 |
| Tschetter, LK | 1 |
| Barlow, JF | 1 |
| Torosian, MH | 1 |
| Jalali, S | 1 |
| Nguyen, HQ | 1 |
| Posner, M | 1 |
| Slapak, CA | 1 |
| Browne, MJ | 1 |
| Clark, JW | 1 |
| Curt, G | 1 |
| Weitberg, A | 1 |
| Calabresi, P | 1 |
| Cummings, FJ | 1 |
| Wiemann, M | 1 |
| Urba, S | 1 |
| Futami, H | 1 |
| Jansen, R | 1 |
| MacPhee, MJ | 1 |
| Keller, J | 1 |
| McCormick, K | 1 |
| Longo, DL | 1 |
| Oppenheim, JJ | 1 |
| Ruscetti, FW | 1 |
| Wiltrout, RH | 1 |
| Price, LA | 1 |
| Hill, BT | 1 |
| Chen, JZ | 1 |
| Sonis, ST | 1 |
| Tracey, C | 1 |
| Shklar, G | 1 |
| Jenson, J | 1 |
| Florine, D | 1 |
| Jones, RB | 1 |
| Shpall, EJ | 1 |
| Shogan, J | 1 |
| Affronti, ML | 1 |
| Coniglio, D | 1 |
| Hart, L | 1 |
| Halperin, E | 1 |
| Iglehart, JD | 1 |
| Moore, J | 1 |
| Gockerman, J | 1 |
| Yamada, K | 1 |
| Takahama, H | 1 |
| Nakai, O | 1 |
| Takanashi, T | 1 |
| Hosoya, T | 1 |
| Inoue, Y | 1 |
| Sawada, T | 1 |
| Shimizu, T | 1 |
| Ishiguro, M | 1 |
| Wakatsuki, T | 1 |
| Hamazoe, R | 1 |
| Shimizu, N | 1 |
| Maeta, M | 1 |
| Koga, S | 1 |
| Gui, GF | 1 |
| Ibayashi, J | 1 |
| Matsuoka, T | 1 |
| Ishikawa, M | 1 |
| Wakui, A | 1 |
| Ogoshi, K | 1 |
| Sakai, Y | 1 |
| Jinushi, K | 1 |
| Kim, R | 1 |
| Toi, M | 1 |
| Saeki, K | 1 |
| Yoshinaka, K | 1 |
| Yanagawa, E | 1 |
| Niimoto, M | 1 |
| Hattori, T | 2 |
| De Vecchis, L | 1 |
| Nunziata, C | 1 |
| Ricci, F | 1 |
| Cucchiara, G | 1 |
| Picconi, A | 1 |
| Bonmassar, G | 1 |
| Lagomarsino Caprino, M | 1 |
| Bonmassar, E | 1 |
| Arai, Y | 1 |
| Endo, T | 1 |
| Miyake, Y | 1 |
| Sakamoto, K | 1 |
| Kido, C | 1 |
| Leyva, A | 1 |
| Laurensse, E | 1 |
| Lokich, J | 1 |
| Bern, M | 1 |
| Anderson, N | 1 |
| Wallach, S | 1 |
| Moore, C | 1 |
| Beauchamp, K | 1 |
| Williams, D | 1 |
| Swain, SM | 1 |
| Sorace, RA | 1 |
| Bagley, CS | 1 |
| Danforth, DN | 1 |
| Bader, J | 1 |
| Wesley, MN | 1 |
| Steinberg, SM | 1 |
| Lippman, ME | 1 |
| Rustum, YM | 1 |
| Bruckner, H | 1 |
| Stablein, D | 1 |
| Chapman, J | 1 |
| Garland, M | 1 |
| Pederson, B | 1 |
| Demitrish, MM | 1 |
| Chinn, B | 1 |
| Ward, D | 1 |
| Rocchio, R | 1 |
| Kunii, Y | 1 |
| Kikuchi, K | 1 |
| Kasai, Y | 1 |
| Abe, O | 1 |
| Kondo, T | 1 |
| Inokuchi, K | 1 |
| Komi, N | 1 |
| Moliterni, A | 1 |
| Martoni, A | 1 |
| Rani, P | 1 |
| Ercolino, L | 1 |
| Canova, N | 1 |
| Pannuti, F | 1 |
| van der Gaast, A | 1 |
| Planting, AS | 1 |
| Stoter, G | 1 |
| Patakfalvi, A | 1 |
| Gelencsér, E | 1 |
| Sípos, J | 1 |
| Bertrand, M | 1 |
| Doroshow, JH | 1 |
| Multhauf, P | 1 |
| Blayney, DW | 1 |
| Carr, BI | 1 |
| Cecchi, G | 1 |
| Goldberg, D | 1 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Metter, G | 1 |
| Sugarbaker, PH | 1 |
| Gianola, FJ | 1 |
| Barofsky, I | 1 |
| Wesley, R | 1 |
| Kvols, LK | 1 |
| Matsuo, T | 1 |
| Kurahashi, Y | 1 |
| Nishida, S | 1 |
| Hayami, T | 1 |
| Takagi, T | 1 |
| Dy, C | 1 |
| Gil, A | 1 |
| Algarra, SM | 1 |
| Aparicio, LA | 1 |
| Calvo, F | 1 |
| Herranz, P | 1 |
| Robbins, TJ | 1 |
| Bowen, D | 1 |
| Bui, QQ | 1 |
| Tran, MT | 1 |
| Ahlgren, JD | 1 |
| Tancini, G | 1 |
| Brambilla, C | 1 |
| Lavin, PT | 1 |
| Brunner, KW | 1 |
| Korman, DB | 1 |
| Borisov, AI | 1 |
| Maslova, IA | 1 |
| Pines, EV | 1 |
| Kalser, MH | 1 |
| Ellenberg, SS | 1 |
| Metz, R | 1 |
| Delgado, M | 1 |
| Keiling, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Misset, JL | 1 |
| Grimbert, J | 1 |
| Mathe, G | 1 |
| Karrer, K | 2 |
| Pridun, N | 1 |
| Zwintz, E | 1 |
| Gailani, S | 2 |
| Leone, L | 2 |
| Stutz, FH | 1 |
| Blom, J | 1 |
| Ellerby, RA | 2 |
| Davis, HL | 2 |
| Ramirez, G | 2 |
| Holland, JF | 1 |
| Burningham, R | 1 |
| Larsen, V | 1 |
| Priestman, TJ | 1 |
| Gerner, RE | 1 |
| Moore, GE | 2 |
| Horn, Y | 1 |
| Halden, A | 1 |
| Gordan, GS | 1 |
| Karjalainen, J | 1 |
| Wasastjerna, C | 1 |
| Di Pietro, S | 1 |
| De Palo, GM | 1 |
| Gennari, L | 1 |
| Molinari, R | 1 |
| Damascelli, B | 1 |
| Fujimoto, S | 1 |
| Miyoshi, T | 1 |
| Nomura, Y | 1 |
| Akao, T | 1 |
| Ito, B | 1 |
| Reed, ML | 1 |
| Vaitkevicius, VK | 2 |
| Kovach, JS | 1 |
| Dines, DE | 1 |
| Karev, N | 1 |
| Blokhina, N | 1 |
| Voznyi, E | 1 |
| Perscin, M | 1 |
| Nadler, SH | 2 |
| Weiss, AJ | 1 |
| Mastrangelo, MJ | 1 |
| Cohn, I | 1 |
| Chernyĭ, VA | 1 |
| Carter, AC | 1 |
| Goldenberg, IS | 1 |
| Segaloff, A | 1 |
| Piro, AJ | 2 |
| Wilson, RE | 2 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 2 |
| Moore, FD | 1 |
| Hill, GJ | 1 |
| Grage, TB | 1 |
| Wilson, W | 1 |
| Karev, NI | 1 |
| Blokhina, NG | 1 |
| Vozny, EK | 1 |
| Pershin, MP | 1 |
| Jacobs, EM | 1 |
| Reeves, WJ | 1 |
| Wood, DA | 1 |
| Pugh, R | 1 |
| Braunwald, J | 1 |
| Cohen, JL | 1 |
| Krant, MJ | 1 |
| Shnider, BI | 1 |
| Matias, PI | 1 |
| Horton, J | 2 |
| Baxter, D | 1 |
| Olson, KB | 1 |
| Hosley, HF | 1 |
| McKinna, JA | 1 |
| Wong, P | 1 |
| Sardesai, S | 1 |
| Voznyĭ, EK | 1 |
| Pivniuk, VM | 1 |
| Buklina, ZP | 1 |
| Ezerskaia, LIa | 1 |
| Denck, H | 1 |
| Ogston, D | 1 |
| Dawson, AA | 1 |
| Philip, JF | 1 |
| Rimm, AA | 1 |
| Slack, NH | 1 |
| Ausman, RK | 1 |
| Jones, R | 1 |
| Schwartz, SA | 1 |
| Perry, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial[NCT02610556] | Phase 2 | 130 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| A Multicenter and Prospective Clinical Trial of Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma[NCT04522050] | Phase 1 | 65 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723] | 441 participants (Actual) | Observational | 2011-08-01 | Completed | |||
| 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial[NCT02512315] | Phase 3 | 192 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Clinical Trial of the Neoadjuvant Standard Chemotherapy 3 FEC 100 + 3 TAXOTERE Protocol Versus the Same Protocol Adapted as a Function of Clinical Response[NCT00425516] | Phase 2 | 264 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
| A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660] | Phase 1/Phase 2 | 84 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy[NCT00216034] | Phase 3 | 255 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients[NCT00687843] | Phase 3 | 480 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma[NCT00503321] | Phase 2/Phase 3 | 13 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Patients' enrollment was not sufficient.) | ||
| A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer[NCT01685489] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to funding sequestered) | ||
| A Phase I Trial of ZD1694 (TOMUDEX® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease[NCT00001341] | Phase 1 | 60 participants | Interventional | 1993-09-30 | Completed | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer[NCT00001239] | Phase 2 | 100 participants | Interventional | 1989-07-31 | Completed | ||
| Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial[NCT00001250] | Phase 2 | 130 participants | Interventional | 1989-12-31 | Completed | ||
| A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150] | Phase 2/Phase 3 | 231 participants (Anticipated) | Interventional | 2020-01-05 | Recruiting | ||
| Phase I Study of Low Kilovoltage Intraoperative Radiation for Patients With Resectable Pancreatic Adenocarcinoma[NCT02599662] | Phase 1 | 12 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma[NCT01553019] | Phase 2 | 2 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer[NCT03167112] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-07-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
9 reviews available for fluorouracil and Leukocytopenia
| Article | Year |
|---|---|
Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Fluorouracil; Humans; Leukopen | 2022 |
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; D | 2016 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
[Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachythera | 2012 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a | 2003 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
The effect of chemotherapeutic agents on wound healing.
Topics: Adrenal Cortex Hormones; Anemia; Animals; Antineoplastic Agents; Azathioprine; Collagen; Cyclophosph | 1981 |
[Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
Topics: Anemia, Aplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B | 1996 |
[Low-dose FP therapy for advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouraci | 1999 |
185 trials available for fluorouracil and Leukocytopenia
| Article | Year |
|---|---|
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colo
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; | 2013 |
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2013 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; D | 2015 |
[Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2008 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
[Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispla | 2008 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neopla | 2009 |
Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2010 |
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study.
Topics: Adult; Age Distribution; Age Factors; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Br | 2009 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; An | 2010 |
A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine; Deoxycytidi | 2010 |
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy | 2010 |
[Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2010 |
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Ad | 2011 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2012 |
Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dietary Supplement | 2012 |
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2002 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2002 |
A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2002 |
Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
[Phase III clinical study of a new anticancer drug atofluding].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Female; Fluorouracil; Humans; Leukopenia; Male; Middle A | 2002 |
Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 2003 |
Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 2003 |
Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 2003 |
Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 2003 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2004 |
Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-R | 2004 |
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug | 2004 |
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2004 |
Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubic | 2004 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Evaluation of toxicities induced by chemotherapy in breast cancer patients.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hor | 2005 |
[A randomized controlled trail of taxol-based combination regimens for advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; F | 2005 |
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose- | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free S | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2006 |
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adeno | 2007 |
[Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2007 |
[Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2007 |
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamid | 2007 |
A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheterizati | 2007 |
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2007 |
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 2007 |
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, | 2008 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fema | 2008 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransfer | 2007 |
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1984 |
Chemotherapy drug dose alteration due to radiation therapy in an adjuvant situation in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1984 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1980 |
Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Diarrhea; Drug Therap | 1980 |
Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Drug Therapy, C | 1980 |
Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; L | 1982 |
Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; Drug Therapy, Combination; Fluo | 1982 |
A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clin | 1982 |
Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery.
Topics: Administration, Oral; Breast Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1981 |
A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor in metastatic breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug | 1994 |
Robust Bayesian methods for monitoring clinical trials.
Topics: Bayes Theorem; Clinical Trials as Topic; Data Collection; Data Interpretation, Statistical; Extracor | 1995 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality | 1995 |
[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Sch | 1995 |
[Early phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr | 1995 |
Treatment of advanced colorectal carcinoma with 5-fluorouracil, leucovorin and Roferon-A: a Southwest Oncology Study Group Study.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Interfer | 1994 |
[A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intrav | 1995 |
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Anorexia; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorou | 1995 |
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; F | 1995 |
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Dacarbazine; Fema | 1994 |
Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1994 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast N | 1994 |
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Doxorubicin | 1994 |
Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors.
Topics: Adenoma, Bile Duct; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms | 1994 |
5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch | 1994 |
Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1993 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 1994 |
Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1993 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1993 |
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1993 |
Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Feasibi | 1993 |
Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 1995 |
Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dr | 1995 |
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl | 1996 |
[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 1996 |
A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Doxoru | 1996 |
Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Astrocytoma; Brain Neoplasms; Female; Fluor | 1996 |
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
Topics: Administration, Oral; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1997 |
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
Topics: Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dise | 1997 |
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1997 |
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, An | 1997 |
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Anemia; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Co | 1996 |
Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 1997 |
[Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration | 1998 |
Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Dacarbazine; Female; F | 1998 |
5-Fluorouracil dose intensification and granulocyte-macrophage colony-stimulating factor in cisplatin-based chemotherapy for relapsed squamous cell carcinoma of the head and neck: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1998 |
Phase II study of paclitaxel in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1998 |
Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubici | 1998 |
Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admini | 1998 |
A phase II trial of preoperative mitomycin, cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1998 |
A phase I/II study of continuous intra-arterial chemotherapy using an implantable reservoir for the treatment of liver metastases from breast cancer: a Japan Clinical Oncology Group (JCOG) study 9113. JCOG Breast Cancer Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubic | 1999 |
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxac | 1999 |
[Concurrent chemoradiotherapy using protracted infusion of low-dose CDDP and 5-FU and radiotherapy for esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1999 |
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1999 |
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; C | 1999 |
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuv | 2000 |
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2000 |
Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2001 |
Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 2001 |
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D | 2002 |
5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.
Topics: Adult; Aged; beta-Alanine; Biotransformation; Bone Marrow; Candidiasis; Female; Flucytosine; Fluorou | 2002 |
[Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administ | 2002 |
Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy--a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Echinacea; Etoposide; | 2002 |
L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).
Topics: Adenocarcinoma, Mucinous; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials | 1977 |
The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Topics: Amenorrhea; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; | 1977 |
Adjuvant combination chemotherapy in primary mammary carcinoma: the CMF program.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, C | 1977 |
Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination | 1975 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem | 1977 |
Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.
Topics: Arylsulfatases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1977 |
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea | 1977 |
Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; D | 1976 |
Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
Topics: Adenocarcinoma; Aged; Alopecia; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evalua | 1976 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ev | 1992 |
Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 1992 |
A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1992 |
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo | 1992 |
5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 1991 |
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto | 1990 |
[Effects of prophylactic intraportal chemotherapy on liver function, blood profile and survival in patients with colo-rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 1989 |
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ | 1989 |
The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal | 1988 |
[Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorourac | 1987 |
Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy. Analysis of drug dosing and toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Breast Neoplasms; Clinical Tri | 1987 |
5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule | 1986 |
Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fema | 1985 |
[Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid | 1985 |
A comparison of 5-fluorouracil administered by slow infusion and rapid injection.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parenteral; Injections, I | 1972 |
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
Topics: Audiometry; Cisplatin; Clinical Trials as Topic; Deafness; Digestive System; Drug Evaluation; Drug T | 1974 |
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cytarabine; Diabetic Ketoacidosis; Diar | 1972 |
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma | 1974 |
A clinical study of fluorouracil.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le | 1968 |
Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease.
Topics: Antibiotics, Antineoplastic; Azo Compounds; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; D | 1970 |
Complications and toxic manifestations of surgical adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Blood Transfusion; Breast Neoplasms; Clinical Trials | 1968 |
Corticosteroids and fluorouracil toxicity.
Topics: Bone Marrow; Clinical Trials as Topic; Diarrhea; Digestive System; Fluorouracil; Humans; Injections, | 1966 |
217 other studies available for fluorouracil and Leukocytopenia
| Article | Year |
|---|---|
Choline deficiency-related multi-omics characteristics are susceptible factors for chemotherapy-induced thrombocytopenia.
Topics: Antineoplastic Agents; Choline; Choline Deficiency; Colorectal Neoplasms; Fluorouracil; Humans; Leuk | 2022 |
Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice.
Topics: Anemia; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diseas | 2020 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Glucuro | 2020 |
Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2021 |
Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2017 |
A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2019 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2019 |
Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog | 2013 |
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C | 2015 |
ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression.
Topics: Aged; ATP-Binding Cassette Transporters; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expre | 2013 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabi | 2013 |
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b | 2014 |
Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Gene Frequency; Genet | 2015 |
Response of Hematopoietic Stem and Progenitor Cells to Reserpine in C57Bl/6 Mice.
Topics: Animals; Bone Marrow; Cyclophosphamide; Fluorouracil; Granulocyte Colony-Stimulating Factor; Granulo | 2016 |
Role of Hematopoietic Stem Cells in Inflammation of the Pancreas during Diabetes Mellitus.
Topics: Animals; Bone Marrow Cells; Cell Differentiation; Cell- and Tissue-Based Therapy; Diabetes Mellitus, | 2016 |
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; ATP-Binding Cassette Tr | 2017 |
Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Dise | 2016 |
A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cisplatin; Disease-Free Survival; Drug Therapy, Combi | 2016 |
Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; | 2017 |
Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuva | 2009 |
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2009 |
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
[Feasibility and short-term efficacy of simplified intensity-modulated radiotherapy and concurrent chemotherapy for neck and upper thoracic esophageal carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell; Cisplati | 2009 |
[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2009 |
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio | 2009 |
Chemotherapy-induced myelotoxicity and incidence of lung metastasis in an animal model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cisplatin; Colonic Ne | 2011 |
Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Atorvastatin; Bac | 2011 |
[Effect of ZL-004 on raising leukocyte count].
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Female; | 2010 |
Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cytokines; Duodenum; Fluorouracil; Ginkgolides; Intestinal | 2011 |
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2011 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Do | 2012 |
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorou | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcino | 2012 |
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2002 |
Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors.
Topics: Adult; Dactinomycin; Drug Resistance, Multiple; Female; Fluorouracil; Humans; Leukopenia; Neoplasm R | 2002 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Adminis | 2003 |
Adjuvant therapy of colon cancer in idiopathic leukopenia.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middl | 2003 |
[Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Toxicity studies of 5-fluorouracil used as an adjunct to surgery.
Topics: Agranulocytosis; Fluorouracil; Humans; Leukopenia; Surgical Procedures, Operative; Uracil | 1960 |
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox | 1964 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
CANCER CHEMOTHERAPY.
Topics: Adrenal Cortex Hormones; Aminopterin; Androgens; Antimetabolites; Antineoplastic Agents; Blood Plate | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
STUDIES ON THE LYMPHOCYTE RESPONSE TO INFLAMMATION.
Topics: Agranulocytosis; Aminopterin; Animals; Azaguanine; Biopsy; Chloramphenicol; Connective Tissue; Cyclo | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Sche | 2003 |
[Four cases of hypopharyngeal cancer treated with docetaxel, cisplatin, and 5-FU followed by radiotherapy and/or neck dissection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; | 2004 |
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2004 |
Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Blood Cells; CD18 Antigens; Cell Adhesion Molecules; | 2004 |
Concurrent chemoradiotherapy with pirarubicin and 5-fluorouracil for resectable oral and maxillary carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Mo | 2004 |
[Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 2005 |
[Hyperfractionated radiotherapy with concurrent chemotherapy for advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deglutit | 2005 |
[Feasibility study of weekly paclitaxel as second-line chemotherapy against 5-FU-refractory gastric carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibil | 2005 |
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2006 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2006 |
[Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 2006 |
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breas | 2006 |
[Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2006 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2006 |
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
Topics: Adult; Aged; Anemia; Black or African American; Breath Tests; Carbon Dioxide; Colorectal Neoplasms; | 2006 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2006 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine.
Topics: Alanine Transaminase; Alkaloids; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Ph | 2008 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2007 |
[Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2008 |
Predicting fluorouracil toxicity: can we finally do it?
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genetic | 2008 |
Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
Topics: Breast Neoplasms; Cell Line; Drug Administration Schedule; Drug Evaluation; Drug Interactions; Drug | 1982 |
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu | 1982 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
[Effect of cepharanthin on peripheral leukocytopenia caused by antineoplastic agents].
Topics: Alkaloids; Animals; Benzylisoquinolines; Fluorouracil; Leukopenia; Lymphoma; Mice; Mice, Inbred Stra | 1983 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1984 |
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce | 1984 |
The effect of time of administration of 5-fluorouracil on leucopenia in the rat.
Topics: Animals; Drug Administration Schedule; Fluorouracil; Leukopenia; Male; Rats; Rats, Inbred Strains | 1984 |
Cisplatin, doxorubicin, and 5-FU in combination for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1984 |
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1984 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco | 1983 |
[Chemotherapy of metastasizing breast cancer. Adriamycin mono and combination therapy after LMFP pretreatment].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Cyclophosp | 1983 |
Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck.
Topics: Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice.
Topics: Animals; Body Weight; Enbucrilate; Female; Fluorouracil; Leukopenia; Mice; Pharmaceutical Vehicles; | 1983 |
Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Ce | 1983 |
Adjuvant chemotherapy (CMF) for breast carcinoma. Patient's compliance and total dose achieved.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1983 |
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; | 1981 |
Combined radical radiation therapy and chemotherapy for primary squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac | 1982 |
[The use of lithium carbonate in mastectomized patients undergoing cancer therapy].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans | 1982 |
Concurrent chemotherapy and radiotherapy for nonmetastatic, Stage IV breast cancer. A pilot study by the Southeastern Cancer Study Group.
Topics: Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, C | 1983 |
Adjuvant chemotherapy (CMF) for breast carcinoma: hematological side effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Carcinoma; Cyclophosp | 1982 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1982 |
High-dose 5-fluorouracil with delayed uridine "rescue" in mice.
Topics: Animals; Colonic Neoplasms; Fluorouracil; Kinetics; Leukopenia; Mice; Mice, Inbred BALB C; Neoplasms | 1982 |
Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil.
Topics: Adenocarcinoma; Female; Fluorouracil; Gastroenteritis; Humans; Leukopenia; Melphalan; Middle Aged; P | 1981 |
Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1980 |
5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Sche | 1980 |
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1980 |
Stopping a clinical trial very early based on unplanned interim analyses: a group sequential approach.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biometry | 1995 |
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua | 1993 |
[Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 1995 |
Two new cases of hyperpyrimidinuria associated with excessive 5-fluorouracil toxicity.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Leukopenia; Mouth Mucosa; Pyrimidines; Stomatitis | 1994 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine.
Topics: Administration, Oral; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopen | 1993 |
[Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; | 1996 |
Suppository delivery of 5-fluorouracil in rectal cancer.
Topics: Administration, Rectal; Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liqu | 1996 |
Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions.
Topics: Animals; Bone Marrow; Crosses, Genetic; Eosinophils; Fluorouracil; Granulocyte-Macrophage Colony-Sti | 1996 |
Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Arabinofuranosyluracil; Dose-Response Relationship | 1996 |
Preliminary report of outpatient weekly adjuvant chemotherapy for high-risk nasopharyngeal carcinoma.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
Myelosuppression in the pig (Sus scrofa): uteroferrin reduces the myelosuppressive effects of 5-fluorouracil in young pigs.
Topics: Acid Phosphatase; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Bone Marrow Cells; Dose-Res | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
Low-dose cisplatin-5-fluorouracil prevents postoperative suppression of natural killer cell activity in patients with gastrointestinal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colectomy; | 1998 |
Evaluation of bovine lactoferrin as a topical therapy for chemotherapy-induced mucositis in the golden Syrian hamster.
Topics: Animals; Antimetabolites, Antineoplastic; Cheek; Cricetinae; Drug Evaluation; Fluorouracil; Immunoco | 1999 |
The leucocyte nadir, a predictor of chemotherapy efficacy?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1999 |
Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Constitution; Body Mass Index; Bod | 2001 |
[Clinical experience of intermittent administration of 5-FU and CDDP to patients with advanced and recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Femal | 2001 |
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neopla | 2001 |
Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: a possible warning sign of severe hematological toxicities?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Fluoro | 2001 |
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 2002 |
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Chalcone; Chalcones; Dose-Response Relationsh | 2002 |
Bleomycin combination chemotherapy in the management of testicular neoplasia.
Topics: Abdominal Neoplasms; Adult; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Dysgerminoma; Fl | 1975 |
[Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer].
Topics: Adult; Altretamine; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leuko | 1978 |
Altered toxicity of 5-fluorouracil following treatment with Corynebacterium parvum.
Topics: Animals; Colony-Stimulating Factors; Fluorouracil; Granulocytes; Hematopoietic Stem Cells; Leukocyte | 1978 |
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1977 |
Assessment of myelotoxic effects of chemotherapy from early leukopenic response: application of a mathematical model for granulopoiesis.
Topics: Antineoplastic Agents; Bone Marrow; Cell Survival; Fluorouracil; Granulocytes; Hematopoiesis; Humans | 1979 |
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1979 |
Allopurinol modulation of high-dose fluorouracil toxicity.
Topics: Allopurinol; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leukopenia | 1979 |
Chemo immunotherapy of advanced breast cancer with BCG.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dr | 1977 |
Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administra | 1978 |
Basal-cell carcinoma. A case unmasked by systemic fluorouracil therapy.
Topics: Administration, Topical; Carcinoma, Basal Cell; Diarrhea; Fluorouracil; Humans; Injections, Intraven | 1976 |
5-fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer.
Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1975 |
Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
Topics: Administration, Oral; Ataxia; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointe | 1975 |
Enhancement of host defense by Y-25510, (+-)-3-[4-(2-dimethylamino-1-methylethoxy)phenyl]-1H-pyrazolo[3,4 -b] pyridine-1-acetic acid, a novel synthetic compound. A comparison with recombinant human granulocyte colony-stimulating factor in 5-fluorouracil-t
Topics: Adjuvants, Immunologic; Animals; Bone Marrow; Female; Fluorouracil; Granulocyte Colony-Stimulating F | 1992 |
Protective effect of ren-shen-yang-rong-tang (Ninjin-youei-to) in mice with drug-induced leukopenia against Pseudomonas aeruginosa infection.
Topics: Animals; Colony-Forming Units Assay; Cyclophosphamide; Drugs, Chinese Herbal; Female; Fluorouracil; | 1992 |
Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice.
Topics: Amifostine; Animals; Cisplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inb | 1992 |
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Ne | 1992 |
Protective effect of SPR-901 (RBS) on the decrease of peripheral leukocyte number in 5-fluorouracil-treated mice.
Topics: Animals; Antineoplastic Agents; Cell Division; Cytokines; Female; Fluorouracil; Glucans; Granulocyte | 1992 |
Comparative effects of a recombinant and a mutein type of granulocyte colony stimulating factor on the growth of Meth-A fibrosarcoma with 5-fluorouracil chemotherapy.
Topics: Amino Acid Sequence; Animals; Combined Modality Therapy; Drug Synergism; Fibrosarcoma; Fluorouracil; | 1992 |
The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil | 1992 |
Intravenous or oral adjuvant CMF for node-positive breast cancer.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemot | 1992 |
Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1991 |
MMAF for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; | 1991 |
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1991 |
[The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer].
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Bone Marrow; Breast | 1990 |
Protein intake and 5-fluorouracil toxicity in tumor-bearing animals.
Topics: Animals; Body Weight; Diarrhea; Dietary Proteins; Female; Fluorouracil; Leukopenia; Mammary Neoplasm | 1990 |
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N | 1990 |
Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Topics: Animals; Carcinoma; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule | 1990 |
Higher average received relative dose intensities of cyclophosphamide, methotrexate and 5-fluorouracil using a 24-hour method: implications for improved cure rates in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat | 1990 |
[Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drugs, Chinese Herbal; Fema | 1990 |
An animal model for mucositis induced by cancer chemotherapy.
Topics: Animals; Cricetinae; Disease Models, Animal; Epithelium; Fluorouracil; Leukopenia; Male; Mesocricetu | 1990 |
The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administr | 1990 |
[Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Evaluati | 1989 |
[Treatment of the side effects of the chemotherapy of trophoblastic tumor with traditional Chinese medicine and western medicine].
Topics: Adult; Dactinomycin; Female; Fluorouracil; Humans; Leukopenia; Medicine, Chinese Traditional; Medici | 1985 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |
Immunochemotherapy of advanced colorectal cancer with alpha-interferon and 5-fluorouracil. 1. Toxicological studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1989 |
[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Flu | 1989 |
Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
Topics: Aged; Bone Marrow; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocy | 1989 |
Cyclophosphamide, methotrexate, and 5-fluorouracil in a three-drug admixture. Phase I trial of 14-day continuous ambulatory infusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Drug | 1989 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1987 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu | 1986 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1988 |
Drug hepatitis of cholestatic type in association with a FAC-regimen for breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced L | 1987 |
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1986 |
[Granulopoietic effects of lentinan in mice: effects on GM-CFC and 5-FU-induced leukopenia].
Topics: Animals; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Fluorouracil; Granulocytes; Len | 1987 |
Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Eval | 1986 |
Modulation of high-dose methotrexate toxicity by a non-toxic level of 5-fluorouracil.
Topics: Animals; Body Weight; Erythrocyte Count; Fluorouracil; Hematocrit; Hemoglobins; Leukocyte Count; Leu | 1986 |
5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1986 |
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neopla | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
[Therapy of bronchial carcinoma. Intermittent high-dosage polychemotherapy of bronchial carcinoma in combination with radical surgery for the prevention of recurrences and in primarily inoperable patients].
Topics: Adult; Aged; Antineoplastic Agents; Austria; Bronchial Neoplasms; Cyclophosphamide; Female; Fluorour | 1973 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Combination chemotherapy in disseminated carcinoma of the breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Stu | 1974 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
Multiple-drug therapy for malignant solid tumors in adults.
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Leukopenia | 1973 |
Leucopoietic effect of calusterone (7 beta, 17 alpha-dimethyltestosterone) in women with advanced breast cancer.
Topics: Administration, Oral; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Inj | 1973 |
The etiocholanolone test for prediction of the leukopenic effect of cytoxic drugs.
Topics: Adult; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Depression, Chemical; Etiocholanolone | 1973 |
Cancer chemotherapy by intra-arterial infusion with adriamycin.
Topics: Adult; Alopecia; Anemia; Doxorubicin; Electrocardiography; Female; Femoral Artery; Fluorouracil; Hea | 1973 |
Intra-arterial cancer chemotherapy with combined anticancer agents.
Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Cytarabine; Deoxycytidine; Drug Therapy, Combination | 1973 |
Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; | 1974 |
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal | 1974 |
[Comparative evaluation of the efficacy of fluorofur (Ftorafur) and 5-fluorouracil (5-ftouracil) in the treatment of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Diarrhea; Drug Evaluation; Female; Fluorouracil; Furans; Hu | 1974 |
Five-drug therapy in advanced breast cancer: factors influencing toxicity and response.
Topics: Administration, Oral; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug The | 1974 |
[The morphologic composition of peripheral blood following intra-arterial infusion of 5-fluorouracil and alkylating preparations in stomach cancer patients].
Topics: Anemia; Fluorouracil; Humans; Leukopenia; Melphalan; Nitrogen Mustard Compounds; Stomach Neoplasms; | 1970 |
Phase I study of phenesterin (NSC-104469).
Topics: Administration, Oral; Adult; Aged; Androgens; Antineoplastic Agents; Blood Cell Count; Blood Platele | 1971 |
Sequential 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and 5-fluorouracil (NSC 19893) therapy of gastrointestinal cancer.
Topics: Cyclohexanes; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leukopenia; Nitroso Compounds; Nitro | 1972 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin | 1972 |
Experience with ftorafur treatment in breast cancer.
Topics: Breast Neoplasms; Diarrhea; Female; Fluorouracil; Furans; Humans; Injections, Intravenous; Leukopeni | 1972 |
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D | 1971 |
Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil.
Topics: Adrenal Insufficiency; Adrenalectomy; Adult; Aged; Alopecia; Breast Neoplasms; Cortisone; Cyclophosp | 1971 |
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Fluorouracil; Human | 1971 |
The use of chemotherapy in advanced carcinoma of the rectum.
Topics: Cyclophosphamide; Fluorouracil; Humans; Injections, Intra-Arterial; Leukopenia; Male; Mechlorethamin | 1969 |
Clinical immunologic responsiveness in malignant disease. I. Delayed hypersensitivity reaction and the effect of cytotoxic drugs.
Topics: Adolescent; Adult; Aged; Antigens; Antineoplastic Agents; Breast Neoplasms; Candida; Child; Child, P | 1970 |
[Changes in the hematopoietic system during treatment with 5-fluorouracil].
Topics: Fluorouracil; Humans; Leukopenia; Neoplasms; Thrombocytopenia | 1970 |
[Hematopoietic changes following use of fluorouracil in animals with toxic hepatitis].
Topics: Anemia, Aplastic; Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; F | 1970 |
[Further proposals for chemotherapeutic prophylaxis of recurrence of bronchial carcinoma].
Topics: Antibiotics, Antineoplastic; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Leukopenia | 1971 |
Methotrexate and the platelet count.
Topics: Antineoplastic Agents; Azathioprine; Blood Cell Count; Blood Platelets; Fluorouracil; Humans; Leukop | 1968 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
Is toxicity really necessary? II. Source and analysis of data.
Topics: Alkylating Agents; Carbamates; Chlorambucil; Fluorouracil; Humans; Leukocyte Count; Leukopenia; Merc | 1966 |
Patient protection in cancer chemotherapy.
Topics: Adult; Anti-Bacterial Agents; Culture Media; Cyclophosphamide; Fluorouracil; Germ-Free Life; Humans; | 1966 |